c-Maf controls immune responses by regulating disease-specific gene networks and repressing IL-2 in CD4+ T cells

Leona Gabryšová1, Marisol Alvarez-Martinez1, Raphaëlle Luisier2, Luke S. Cox1, Jan Sodenkamp3, Caroline Hosking3, Damián Pérez-Mazliah3, Charlotte Whicher4, Yashaswini Kannan4, Krzysztof Potempa1, Xuemei Wu1, Leena Bhan5, Hagen Wende6, Michael H. Sieweke7,8, Greg Elgar5, Mark Wilson4, James Briscoe9, Vicki Metzis9, Jean Langhorne3, Nicholas M. Luscombe2,10 and Anne O’Garra1,11*

The transcription factor c-Maf induces the anti-inflammatory cytokine IL-10 in CD4+ T cells in vitro. However, the global effects of c-Maf on diverse immune responses in vivo are unknown. Here we found that c-Maf regulated IL-10 production in CD4+ T cells in disease models involving the Th1 subset of helper T cells (malaria), Th2 cells (allergy) and Th17 cells (autoimmunity) in vivo. Although mice with c-Maf deficiency targeted to T cells showed greater pathology in Th1 and Th2 responses, Th17 cell-mediated pathology was reduced in this context, with an accompanying decrease in Th17 cells and increase in Foxp3+ regulatory T cells. Bivariate genomic footprinting elucidated the c-Maf transcription-factor network, including enhanced activity of NFAT; this led to the identification and validation of c-Maf as a negative regulator of IL-2. The decreased expression of the gene encoding the transcription factor RORγt (Rorc) that resulted from c-Maf deficiency was dependent on IL-2, which explained the in vivo observations. Thus, c-Maf is a positive and negative regulator of the expression of cytokine-encoding genes, with context-specific effects that allow each immune response to occur in a controlled yet effective manner.

T

he immune response is under strict control in its regulation of the production of inflammatory mediators that control infection with minimal damage to the host. Subsets of CD4+ helper T cells, including Th1, Th2 and Th17 cells, are critical for the eradication of specific pathogens, but if they are uncontrolled, they can contribute to immunopathology, either during infection or during immune system-mediated diseases. Various regulatory mechanisms are in place to control inappropriate or excessive immune responses, including production of the anti-inflammatory cytokine IL-10 and CD4+ regulatory T cells (Treg cells) expressing the gene encoding the transcription factor (TF) Foxp3. Although distinct molecular pathways direct the development of different effector and regulatory CD4+ T cells, IL-10 is produced by all CD4+ T cell subsets and is therefore not a subset-specific cytokine. Whether IL-10 production is regulated by lineage-specific mechanisms or whether a common TF controls IL-10 in all CD4+ T cell subsets is unclear. Many TFs have been shown to modulate Il10 expression, including c-Maf, a member of the AP-1 (‘activator protein-1’) TF superfamily. c-Maf functions to control an array of biological processes, including lens and bone development, apoptosis, oncogenesis and the immune response. Although c-Maf has been shown to positively regulate Il10 expression in vitro, its effects on Il10 and global gene expression across different immune responses in vivo are unknown.

Here we found that c-Maf regulated IL-10 in vivo in CD4+ T cells from disease models involving Th1 cells (malaria), Th2 cells (allergy) and Th17 cells (autoimmunity) but had context-specific effects on these immune responses beyond its effects on IL-10. Through the use of genomic approaches, we found that c-Maf-deficient CD4+ T cells showed substantial changes in transcriptional activity, including enhanced activity of the TF NFAT, which led to the identification and validation of c-Maf as a negative regulator of IL-2. This provided an explanation for the context-specific effects of c-Maf deficiency on the immune responses, which included decreased Th17 cells, increased Foxp3+ Treg cells and reduced autoimmune pathology in vivo.

Results

Expression of Maf and that of Il10 correlate in all helper T cell and Treg cell subsets. To identify candidate TFs that regulate the expression of Il10 in different CD4+ T cell subsets, we differentiated Th1, Th2, Th17 and T cells in vitro and profiled the following cells by RNA-based next-generation sequencing (RNA-seq): Th1 cells, Th1 cells grown in the presence of IL-27, Th2 cells, Th17 cells, and T cells that produce IL-10 only and were grown in the presence of vitamin D3 and dexamethasone, as well as ex vivo–derived Foxp3+ Treg cells (Fig. 1a–d). We correlated the expression of

1The Francis Crick Institute, Laboratory of Immunoregulation and Infection, London, UK. 2The Francis Crick Institute, Computational Biology Laboratory, London, UK. 3The Francis Crick Institute, Malaria Laboratory, London, UK. 4The Francis Crick Institute, Helminth Immunology Laboratory, London, UK. 5Heidelberg University, Institute of Pharmacology, Heidelberg, Germany. 6Aix Marseille University, CNRS, INSERM, CIFML, Marseille, France. 7Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtzgemeinschaft (MDC), Berlin, Germany. 8The Francis Crick Institute, Developmental Dynamics Laboratory, London, UK. 9UCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, London, UK. 10National Heart and Lung Institute, Imperial College London, London, UK. *e-mail: anne.ogarra@crick.ac.uk
TF-encoding genes to that of Il10 mRNA across all helper T cell and Tm cells (Fig. 1c and Supplementary Table 1). c-Maf, which is encoded by a gene (Maf) that was upregulated upon differentiation (Supplementary Fig. 1), was the strongest candidate as a positive regulator of Il10 (Fig. 1e,f) among TFs previously associated with IL-10. In contrast, no correlation between the expression of Maf and expression of the hallmark cytokine-encoding genes Ifng or Il4 was observed, but, as expected, expression of these effector cytokine-encoding genes showed tight correlation with expression of Tbx21 and Gata3, which encode the Tp1 cells hallmark TF Tbet and Tp2 cell hallmark TF GATA-3, respectively (Fig. 1f). Thus, c-Maf might function as a common regulator of IL-10 in CD4+ T cells regardless of the T cell subset.

c-Maf deficiency in CD4+ T cells affects susceptibility to disease in a context-specific manner. Having identified c-Maf as the strongest candidate as a TF regulator of IL-10, we next sought to determine whether c-Maf is a common regulator of IL-10 in vivo and to what extent c-Maf affects the immune response and associated pathologies. To this end, we investigated the effect of deletion of Maf targeted to CD4+ T cells (Maffl/flCd4-cre) in mouse models of malaria (Tg41 cells), house dust mite (HDM) allergy (Tg2 cells) and experimental autoimmune encephalitis (EAE) (Tg17 cells), which encapsulates a spectrum of immune responses (Fig. 2a–c). In the malaria model, Maffl/flCd4-cre mice showed greater acute-phase pathology than that of Maffl/fl (control) mice, with significant weight loss and decrease in temperature, but c-Maf deficiency in CD4+ T cells had little to no effect on parasite load (Fig. 2d). Similarly, in the HDM allergy model, Maffl/flCd4-cre mice had more total cells (mostly eosinophils) in bronchoalveolar lavage fluid and greater lung pathology (characterized by higher mucus and inflammation scores) than that of Maffl/fl (control) mice (Fig. 2e). Maffl/flCd4-cre mice showed less pathology in the Tg17 EAE model, as demonstrated by less weight loss and lower clinical scores, with overall less-advanced disease than that of Maffl/fl (control) mice (Fig. 2f).

Our findings thus demonstrated that the disease-associated pathology that resulted from Maf deletion targeted to CD4+ T cells was a phenocopy of that of IL-10 deficiency in the malaria model and was in keeping with IL-10’s regulatory role in allergy. In contrast, such deletion of Maf in the EAE setting showed an effect opposite to that reported for IL-10, indicative of an additional role for c-Maf in Tg17 responses that contributed to pathology.

Deciphering c-Maf-driven transcriptional programs within dominant disease-associated immune responses. To better understand the disease-specific effects of the deletion of Maf, we performed RNA-seq analysis of purified CD4+ T cells isolated from the spleen, lungs and the central nervous system in the three disease models noted above. Hierarchical clustering revealed that the greatest variations in gene expression were driven by each disease (Fig. 3a and Supplementary Data). However, a distinct separation of gene expression in CD4+ T cells from Maffl/flCd4-cre mice from that in such cells from Maffl/fl (control) mice was not discernible, except in the malaria model (Fig. 3a). Indeed, 78% of the variance captured by the first two singular-value-decomposition components clustered the samples according to the disease-specific immune response, as shown by biological pathway analysis (Fig. 3b–d and Supplementary Table 2). The fourth component, although it was accountable for only 3% of the variance (Fig. 3b–d and Supplementary Table 2), segregated the samples according to Maf deficiency, irrespective of the disease (Fig. 3b,d). This component contained both downregulated genes, including those encoding transcriptional regulators and molecules in the immune response (such as Il10), and upregulated genes, such as those encoding molecules with proliferative function (E2f1, Runx3 and Il2ra) (Fig. 3d). Thus, although the immune response dominated over the deletion of Maf, c-Maf did contribute to a small but coherent change in gene expression across all three diseases in vivo that included changes in the expression of Il10, which confirmed the in vitro findings.

c-Maf regulates Il10 expression in CD4+ T cells in vivo with wider disease-specific effects. Subsequent comparison of genes expressed differentially in Maffl/flCd4-cre mice relative to their expression in Maffl/fl (control) mice in all three disease models showed only 48 overlapping genes, in contrast to the overall sizable perturbation of 2,635 genes in the malaria model, 1,073 genes in the HDM allergy model and 265 genes in the EAE model, many of which were in fact disease specific and were both upregulated and downregulated in the absence of c-Maf (Fig. 4a, Supplementary Fig. 2, Supplementary Table 3 and Supplementary Data). To further characterize the context-specific effects of the deletion of Maf, we investigated in greater detail the differentially expressed genes encoding members of the TF, cytokine and membrane-receptor families (Fig. 4b–d and Supplementary Table 4). 12% of the genes encoding molecules involved in the immune response had known relationships with c-Maf. The majority of differences in the expression of genes encoding molecules not involved in the immune response for which c-Maf was accountable, observed predominantly in the malaria model, had not previously been recognized (Fig. 4b–d). The molecules encoded by these genes control general biological processes such as the cell cycle (E2f1, E2f2, E2f7 and E2f8) or circadian rhythm (Bhlhe40) but might nonetheless contribute to the net effect of c-Maf on the immune response.

Il10 expression was significantly lower in CD4+ T cells across all three diseases in the absence of c-Maf (Fig. 4a,e–g and Supplementary Fig. 2a), as we had also demonstrated in IL-27-driven CD4+ T cells and Tg17 cells in vitro (Supplementary Fig. 1a). Similarly, the production of IL-10 protein by Tg17 cells and Tg2 cells was reduced in response to deletion of Maf in the malaria disease model and HDM allergy disease model, respectively (Fig. 5a–c). In the EAE model, however, IL-10 protein was not detectable in CD4+ T cells, in keeping with the low levels of Il10 mRNA observed in this model (Fig. 4g). Although c-Maf had a uniform role in the induction of IL-10, it showed differing effects on hallmark TFs involved in the immune response for which c-Maf was accountable, observed predominantly in the malaria model, had not previously been recognized (Fig. 4b–d). The molecules encoded by these genes control general biological processes such as the cell cycle (E2f1, E2f2, E2f7 and E2f8) or circadian rhythm (Bhlhe40) but might nonetheless contribute to the net effect of c-Maf on the immune response.

Il10 expression was significantly lower in CD4+ T cells across all three diseases in the absence of c-Maf (Fig. 4a,e–g and Supplementary Fig. 2a), as we had also demonstrated in IL-27-driven CD4+ T cells and Tg17 cells in vitro (Supplementary Fig. 1a). Similarly, the production of IL-10 protein by Tg17 cells and Tg2 cells was reduced in response to deletion of Maf in the malaria disease model and HDM allergy disease model, respectively (Fig. 5a–c). In the EAE model, however, IL-10 protein was not detectable in CD4+ T cells, in keeping with the low levels of Il10 mRNA observed in this model (Fig. 4g). Although c-Maf had a uniform role in the induction of IL-10, it showed differing effects on hallmark TFs involved in the immune response for which c-Maf was accountable, observed predominantly in the malaria model, had not previously been recognized (Fig. 4b–d). The molecules encoded by these genes control general biological processes such as the cell cycle (E2f1, E2f2, E2f7 and E2f8) or circadian rhythm (Bhlhe40) but might nonetheless contribute to the net effect of c-Maf on the immune response.

Il10 expression was significantly lower in CD4+ T cells across all three diseases in the absence of c-Maf (Fig. 4a,e–g and Supplementary Fig. 2a), as we had also demonstrated in IL-27-driven CD4+ T cells and Tg17 cells in vitro (Supplementary Fig. 1a). Similarly, the production of IL-10 protein by Tg17 cells and Tg2 cells was reduced in response to deletion of Maf in the malaria disease model and HDM allergy disease model, respectively (Fig. 5a–c). In the EAE model, however, IL-10 protein was not detectable in CD4+ T cells, in keeping with the low levels of Il10 mRNA observed in this model (Fig. 4g). Although c-Maf had a uniform role in the induction of IL-10, it showed differing effects on hallmark TFs involved in the immune response for which c-Maf was accountable, observed predominantly in the malaria model, had not previously been recognized (Fig. 4b–d). The molecules encoded by these genes control general biological processes such as the cell cycle (E2f1, E2f2, E2f7 and E2f8) or circadian rhythm (Bhlhe40) but might nonetheless contribute to the net effect of c-Maf on the immune response.
Fig. 1 | Expression of Maf and that of Il10 correlate in all helper T cell and Treg cell subsets. a, Flow-cytometry analysis of cytokine staining of the following cells (above plots): naive CD4+ T cells (Naive); in vitro-differentiated T0 cells treated with antibody blockade of the cytokines IL-12p40, IFN-γ, IL-4, IL-6 and TGF-β (T0+ block), T0 cells, T1 cells, T1 cells treated with IL-27 (T1+IL-27), T2 cells, T17 cells, and CD4+ T cells treated with vitamin D3 and dexamethasone (VitD3+Dex) (n = 2 independent experiments per group), as well as IL-10+ or IL10+ Treg cells ex vivo (n = 3 independent experiments). Numbers in quadrants indicate percent cells in each. b, RNA-seq analysis of CD4+ T cells as in a (above plots), showing the mean expression (presented as read counts normalized to the median value, as baseline; key) of 12,742 genes in naive CD4+ T cells (n = 2 independent experiments, with three culture wells in one experiment), in vitro-differentiated T0, T1 cells treated with blockade as in a (n = 2 independent experiments with three culture wells in each), T0 cells (n = 2 independent experiments), T1 cells (n = 2 independent experiments), T1 cells treated with IL-27 (n = 2 independent experiments), T2 cells (n = 2 independent experiments), T17 cells (n = 2 independent experiments with three culture wells in each) and CD4+ T cells treated with vitamin D3 and dexamethasone (n = 2 independent experiments) after culture alone (0h) or after 0.5, 2 or 6h of re-stimulation in vitro (below plots), and in Foxp3+ IL-10+ or IL-10− Treg cells ex vivo (n = 3 independent experiments per group). c, d, Expression of Il10 (c) and of genes encoding hallmark cytokines or TFs (perimeter of key at far right) at 6h after restimulation (d) in the various CD4+ T cell populations in b (bar and shape colors in c,d match those above the plots in b); results in d are presented as the log2 value of the mean expression value per population (numbers in key at far right). Each symbol (c) represents an individual culture well. e, Positive and negative Pearson correlation (key) of the expression of genes encoding various TFs (below plot; ranked (left to right) by correlation) with the expression of Il10 across all the CD4+ T cell populations in b (top row); black (bottom row) indicates TFs previously associated with IL-10. f, Linear-regression analysis of the expression of Maf versus that of Il10 or genes encoding hallmark cytokines (top row) or of the expression of genes encoding master regulators of helper T cell subsets and genes encoding hallmark cytokines (bottom row) in cells as in b (left key) at various times as in b (right key); each symbol represents the mean read counts per CD4+ T cell subset per time point in b; shaded areas indicate the 95% confidence interval. Data are from n = 2 independent experiments per group (Naive, T0+ block, T0, T1, T1+IL-27, T2, T17 and VitD3+Dex) or n = 3 independent experiments per group (Treg IL-10+ and Treg IL-10−) (c–f, mean ± s.d. in c).
c-Maf deficiency in CD4+ T cells affects susceptibility to disease in a context-specific manner. a–c, Protocol for the models with Maffl/fl and Maffl/flCd4-cre mice: intraperitoneal (i.p.) injection of Plasmodium chabaudi–infected red blood cells (RBC) into mice to induce malaria (a); treatment of mice intraperitoneally (i.p.) with HDM in alum and intratracheally (i.t.) with HDM to induce allergy (b); and treatment of mice intraperitoneally (i.p.) with myelin oligodendrocyte glycoprotein (MOG) in complete Freund’s adjuvant (CFA) plus pertussis toxin (PTx) to induce EAE disease (c). d, Change in body weight (left), body temperature (middle) and parasitemia (right) at various times (horizontal axis) during the infection of mice (key) with P. chabaudi as in a (n = 14 mice per group). e, Total cells and eosinophils (differential counts of Giemsa-stained cells) in the bronchoalveolar fluid (BALF) of mice (key) after treatment with PBS or HDM challenge as in b (horizontal axis) (left two plots; n = 5 experiments); microscopy of lung sections from such mice (above images and left margin), stained with H&E or with Alcian blue plus periodic acid–Schiff (AB-PAS) (below images) (middle images); and cumulative total inflammation score (from H&E analysis) and mucus score (from AB-PAS analysis) in such mice (right two plots). Each symbol (left and right) represents an individual mouse. Scale bars (middle), 500 μm. *P < 0.05 (two-tailed Mann-Whitney test). f, Change in body weight (left) and clinical score (middle; includes linear regression) at various times (horizontal axis) during the induction of EAE as in c (n = 10 mice per group), and distribution of disease severity in such mice (right) (key: no EAE (None), score < 2; mild EAE, score = 2–3; severe EAE, score > 4; n = 28 mice per group). *P ≤ 0.035 (F-test). Data are from (d, e (left and right), f) or representative of (e (middle)) three biological replicate experiments per disease model (mean ± s.e.m. in df; mean ± s.d. in e).

The context specificity of c-Maf in the immune response is driven by direct and indirect mechanisms. To identify the molecular mechanisms whereby c-Maf affects gene regulation in CD4+ T cells in vivo, we used the assay for transposase-accessible chromatin plus sequencing (ATAC-seq) to reveal functionally active genomic regions. Consistent with the RNA-seq profile (Fig. 3a), hierarchical clustering of ATAC-seq data revealed that the open-chromatin landscape was dominantly driven by each disease and that a distinct separation between Maf-sufficient CD4+ T cells and Maf-deficient CD4+ T cells in their chromatin accessibility was observed only in the malaria model (Fig. 6a). This might potentially be explained by the finding of increased chromatin accessibility in the Maffl/flCd4-cre condition (Fig. 6b), which would in part also explain the larger number of dysregulated genes in this model (Fig. 4a). Although c-Maf did not itself show evidence of inducing chromatin remodeling (Fig. 6b), de novo motif discovery using MEME-ChIP software revealed that the remodeled loci showed enrichment for Runx motif (E value = 3.8 × 10−62) (Fig. 6b), which suggested that Runx factors might account for increased open chromatin in the malaria model through their known interactions with epigenetic modifiers. However, such changes in chromatin accessibility were not exclusively responsible for the transcriptional changes observed by RNA-seq, since only a small fraction of the differentially expressed genes were associated with altered ATAC-seq peaks in any of the models (Supplementary Fig. 4). Together these data indicated that c-Maf acted via activation and repression of gene expression and that its context-specific action was defined by the accessible chromatin landscape dictated by the type of immune response.

We further integrated our RNA-seq data and ATAC-seq data with data obtained by analysis of c-Maf with chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) and motif data to identify genes that were targets of c-Maf; these results were confirmed by BETA software (which integrates ChIP-seq analyses and gene-expression data to identify target genes) (Supplementary Fig. 5, Supplementary Table 5 and Supplementary Data). Differentially expressed genes showed enrichment for
putative c-Maf-binding sites (Supplementary Table 6), which indicated that c-Maf was able to have direct effects and was responsible for the transcriptional changes seen. Specifically, the combined evidence of open chromatin coincident with binding of c-Maf to the Il10 locus confirmed c-Maf as a direct positive regulator of Il10 in vivo (Fig. 6c,d). However, although we found that Il4 and Rorc were...
Fig. 4 | c-Maf regulates IL10 expression in CD4+ T cells in vivo with wider disease-specific effects. a. Quantification (numbers in plots) and overlap of genes differentially expressed, upregulated or downregulated (above plots) in CD4+ T cells from Maffl/flCd4-cre mice relative to their expression in such cells from Maffl/fl mice in the malaria, HDM allergy and EAE models (key), with the cutoff of an absolute change in expression of ≥1.5-fold and a P value of <0.05 (two-tailed moderated t-test). b–d, Networks of differentially expressed genes encoding TFs, cytokines and trans-membrane receptors (key), in the malaria model (b), HDM allergy model (c) and EAE model (d); symbol size indicates mean read number; red lines indicate known interactions with c-Maf; genes associated with Tc1 cells, Th2 cells, Tc17 cells, Treg cells and Thy1 cells, as well as those with T cell antigen receptor (TCR) and costimulation (Costim) and IL-2 signaling, are subgrouped within the set of genes encoding molecules with immunological function. e–g, Expression of genes encoding Tc1 cell, Th2 cell, Tc17 cell and Thy1 cell master regulator TFs or hallmark cytokines (categories above plots) in CD4+ T cells from Maffl/flCd4-cre and Maffl/fl mice (key) in the malaria model (e), HDM allergy model (f) and EAE model (g), presented as normalized read counts (cutoffs as in a), BT, below filtering threshold. *P < 0.05 (two-tailed moderated t-test). Each symbol represents an individual mouse (malaria) or a pool of up to 5 mice (HDM) or 15 mice (EAE). Data are from n = 1 experiment (malaria) or n = 3 experiments with n = 3 independent mice (malaria) or n = 3 biological replicates (HDM and EAE) per genotype (mean ± s.d. in e–g).
also direct targets of c-Maf, the effect of c-Maf on the expression of Il2 and Foxp3 was indirect, with no evidence of direct binding to these loci (Fig. 6c,d and Supplementary Fig. 6). Thus, the observed changes in Runx expression relative to Foxp3 expression that resulted from c-Maf deficiency were probably due to indirect mechanisms.

**IL-2 is a c-Maf target.** To identify candidate TFs responsible for the indirect effects of c-Maf, we applied ‘bivariate genomic footprinting’ (BaGFoot) software to the ATAC-seq data to assess changes in TF ‘footprint depth’ and accessibility of flanking motifs (Fig. 7a and Supplementary Table 7). TF-binding site motifs that were significant outliers from the multivariate distribution that showed TF binding in the absence of c-Maf different from that in its presence (the control condition) were predominantly context-specific and were more abundant in the malaria model than in the HDM allergy model or EAE model (Fig. 7a), in line with the expression data (Fig. 4a). Moreover, the accessible genomic neighborhood of differentially expressed genes showed significant enrichment for most of these TF motifs, compared with the non-differentially expressed genes (Supplementary Table 8), in the three model diseases after deletion of c-Maf. De novo motif discovery (by MEME-ChIP) identified the motif for the Runx family of TFs as the top match in differentially accessible ATAC-seq peaks in the malaria model (E value = 3.8 × 10^-34) (Fig. 6b). The remodeled loci showed enrichment for the Runx motif (Fig. 6b), and Runx showed enhanced binding (Fig. 7a) and increased expression (Figs. 3a and 4b–d and Supplementary Table 3) in Maf^fl/flCd4-cre mice exclusively in the malaria model. Furthermore, Runx showed a more significant effect on differentially expressed genes than did c-Maf itself (Supplementary Table 8). Thus, Runx might have contributed to the increased pathology in the malaria model by its reported effects on IFN-γ production.

The AP-1 family members BATF, Fdun, Jun and Junt (Fig. 7a and Supplementary Table 8), which are known to directly interact with c-Maf^fl/fl, might further contribute to changes in gene expression, including regulation of Il10. Bhlhe40, a known negative regulator of IL-10 that we found was upregulated in Maf-deficient CD4+ T cells (Supplementary Table 3), also seemed to additionally contribute to the indirect effects of c-Maf in the malaria model and HDM allergy model, as shown by the analysis with BaGFoot software (Fig. 7a and Supplementary Table 8).

In contrast to the context-specific effects on TFs, the NFAT2 motif showed significant differences in the genome-wide footprints (Fig. 7b) and contributed to changes in gene expression in all three disease models (Fig. 7a and Supplementary Table 8). On the basis of the well-known role of NFAT in the regulation of Il2 expression, we concluded that both Il2 and Il2ra were potential direct targets of c-Maf (Fig. 7c). Since IL-2 is known to regulate Foxp3+ Treg cells and Th17 cells, we postulated that the observed increase in Foxp3+ Treg cells and decrease in Th17 cells in the EAE model (Figs. 4g and 5d,e) could have resulted from indirect effects of c-Maf on IL-2. To test that hypothesis and confirm the results of
our genome-network analysis, we investigated the effect of deletion of c-Maf on Il2 expression. Maf-deficient CD4+ T cells had higher expression of Il2 mRNA than that of their Maf-sufficient (control) counterparts under all differentiation conditions, accompanied by a reciprocal decrease in Rorc expression and an increase in Foxp3 expression under Tfh17 conditions and induced Treg cell conditions, respectively, in vitro (Fig. 7d). The decreased expression of Rorc observed in Maf-deficient Tfh17 cells was caused indirectly via the action of IL-2, since this effect was abolished by neutralization of IL-2 (Fig. 7d); this resolves published findings suggesting that c-Maf negatively regulates gene expression during Tfh17 differentiation.

Discussion

Here we combined comprehensive transcriptional, epigenomic and TF-binding analyses of CD4+ T cells from mice with Maf-deficiency targeted to such cells to show that c-Maf provides a common mechanism for direct transcriptional regulation of Il10 expression in CD4+ T cells in vivo in models of Tfh1, Tfh2 and Tfh17 responses. Furthermore, we identified a broad context-specific gene-expression program regulated by c-Maf beyond its effects on IL-10, which explained the unexpected diverse effects on each disease phenotype. We demonstrated that c-Maf in fact functioned by both direct mechanisms and indirect mechanisms to regulate gene expression and to control the effector phenotype in Tfh1 and Tfh2 responses, which, in conjunction with IL-10, might reinforce the distinct disease outcomes observed.

In the malaria model, Tfh1 cell–associated genes were regulated indirectly by a c-Maf-driven gene network that reinforces Tfh1 cell activity to combat pathology. For example, Bhlhe40, which encodes a molecule associated with circadian rhythm, as well as negative...
regulation of IL-10\(^{36}\), and Runx3, which encodes a TF key to the maximal production of IFN-\(\gamma\)\(^{41}\) in T\(_{H}1\) cells, were found to be upregulated and have increased activity in the absence of c-Maf. In contrast, we found that T\(_{H}2\) cell–associated genes were direct targets of c-Maf, in keeping with its earlier definition as a positive regulator of expression of genes encoding T\(_{H}2\) cell–associated cytokines\(^{36}\). However, c-Maf co-regulated IL-10 and T\(_{H}2\) cell-associated genes; thus, the decrease in T\(_{H}2\) cells producing both IL-4 and IL-10 observed in the absence of c-Maf might account for the overall detrimental effect on the disease pathology in the HDM allergy model. While deletion of c-Maf resulted in increased susceptibility to the experimental effect on the disease pathology in the HDM allergy model.

\(\text{Fig. 7 | Identification and validation of IL-2 as a c-Maf target from inferred c-Maf regulated TF networks. a, BaGFoot analysis of TFs with potential genome-wide changes in binding within ATAC-seq peaks in CD4\(^{+}\) T cells from Maf\(^{fl/fl}\) mice relative to that in such cells from Maf\(^{fl/fl}\)/Cd4\(-\)cre mice in the malaria, HDM allergy and EAE models (above plots), presented as the change in ‘footprint depth’ (\(-\Delta\)FPD) plotted against the change in the accessibility of flanking motifs (change in ‘flanking accessibility’ (\(\Delta\)FA)); wedges along axes indicate direction and degree of change in TF binding in Maf\(^{fl/fl}\) mice (filled) and Maf\(^{fl/fl}\)/Cd4\(-\)cre mice (open); dark shading in plot indicates a region with no change in TF motif parameters, and light shading indicates a region in which most TF motifs were located. P values (top key) indicate statistical confidence assigned to the differential binding of a TF in each disease model (Supplementary Data). Bold font in plot indicates TFs for which in the accessible genomic neighborhood of differentially expressed genes showed enrichment for that TF motif (\(q < 0.05\) (one-tailed Fisher’s exact test)). b, Metaplot of ATAC-seq footprints containing an NFATc2 motif match in CD4\(^{+}\) T cells from Maf\(^{fl/fl}\) and Maf\(^{fl/fl}\)/Cd4\(-\)cre mice (key) in the malaria model (top; yellow and orange), the HDM allergy model (middle; light and dark green) and EAE model (bottom; light and dark blue); horizontal dashed lines represent the sum of transposase insertions across the footprint region in each condition; vertical dashed lines represent the motif boundaries. c, Genome-browser tracks of read coverage of RNA-seq and ATAC-seq in CD4\(^{+}\) T cells from Maf\(^{fl/fl}\)/Cd4\(-\)cre and Maf\(^{fl/fl}\)/Cd4\(-\)cre mice (key) left untreated (None) or in the malaria, HDM allergy and EAE models (left margin), presented as an overlay, and matched to c-Maf ChIP-seq analysis (bottom) and motif sites (right margin). d, Expression of Il2 (all cells), Rorc (T\(_{H}1\) cells and Foxp3 (induced T\(_{H}1\) cells) in naive CD4\(^{+}\) T cells obtained from Maf\(^{fl/fl}\) and Maf\(^{fl/fl}\)/Cd4\(-\)cre mice and differentiated in vitro under T\(_{H}0\) cell, T\(_{H}1\) cell, T\(_{H}1\) cell plus IL-27, T\(_{H}2\) cell, T\(_{H}17\) cell and induced T\(_{H}1\) cell (iT\(_{H}1\)) conditions (above plots; top eight plots) and of Rorc in T\(_{H}17\) cells differentiated in vitro in the presence (Anti-IL-2) or absence (Control) of anti-IL-2 (bottom left); results are presented relative to those of the control gene Hprt. Each symbol represents an individual culture well. * \(P < 0.05\), ** \(P < 0.01\), *** \(P < 0.001\) and **** \(P < 0.0001\) (two-tailed unpaired t-test (top eight plots) or one-way ANOVA (bottom left)). Data are from \(n = 1\) experiment (malaria) or \(n = 3\) experiments with \(n = 3\) independent mice (malaria) or \(n = 3\) biological replicates (HDM and EAE) per genotype (a–c) or are from two (T\(_{H}2\) or three (all others) independent experiments with \(n = 3\) culture wells per condition (d); mean ± s.d.).
Further inference of c-Maf regulatory networks showed that a proportion of the transcriptional changes seen could have been a result of the increased NFAT activity observed in Maf-deficient CD4+ T cells across all disease models. Given the well-known role of NFAT in the regulation of IL2 expression and our finding that both IL2 and II2ra were direct targets of c-Maf, we confirmed the predictions of the regulatory networks to demonstrate a role for c-Maf as a negative regulator of IL-2. Collectively our findings suggest that by negatively regulating IL2 expression, c-Maf has overarching context-specific effects on immune responses, on the one hand limiting Tn1 and Tn2 responses that depend strongly on IL-2 and on the other hand allowing the development of a Tn17 response by regulating Rorc expression and Foxp3+ Treg cells. These findings are in apparent contrast to published studies showing that deletion of c-Maf targeted to Foxp3+ cells results in fewer RorcFoxp3+ Treg cells, which, given the nature of their systems, could not reveal the more global effects of c-Maf on gene expression in CD4+ T cells during distinct immune responses that we have reported here. Despite that, these findings reinforce our concept that c-Maf has context-specific effects on the immune response.

Together our findings have demonstrated a broad yet context-specific role for c-Maf in regulating gene expression that allows each type of T cell effector immune response to occur in a controlled yet effective manner. Our study has also highlighted the utility of genome-wide analyses that span multiple layers of transcriptional regulation to reveal and validate gene networks.

Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi.org/10.1038/s41590-018-0083-5.

Received: 29 January 2018; Accepted: 8 March 2018; Published online: 16 April 2018

References
1. Sher, A. & Coffman, R. L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu. Rev. Immunol. 10, 385–409 (1992).
2. Littman, D. R. & Rudensky, A. Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845–858 (2010).
3. Zhu, J., Yamashita, T. & Paul, W. E. Differentiation factor CD4 T cell populations. Annu. Rev. Immunol. 28, 445–489 (2010).
4. Gabrysova, L., Howes, A., Saraiva, M. & O’Garra, A. The regulation of IL-10 expression. Curr. Top. Microbiol. Immunol. 380, 157–190 (2014).
5. Jossowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012).
6. Apelth, L. et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11, 854–861 (2010).
7. Ciofani, M. et al. A validated regulatory network for Th17 cell specification. Cell 151, 289–303 (2012).
8. Cipolletta, D. et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue T cells. Nature 486, 549–553 (2012).
9. Jones, E. A. & Flavell, R. A. Distal enhancer elements transcribe intergenic RNA in the IL-10 family gene cluster. J. Immunol. 175, 7437–7446 (2005).
10. Li, P. et al. BATF-JUN is critical for IRF4-mediated transcription in T cells. J. Exp. Med. 202, 1199–1212 (2005).
11. Korn, T. et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 105, 18460–18465 (2008).
12. Coomes. S.M. et al. CD4 Th2 cells are directly regulated by IL-10 during allergic airway inflammation. Mucosal Immunol. 10, 150–161 (2017).
13. Bettelli, E. et al. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161, 3299–3306 (1998).
14. Andris, F. et al. The transcription factor c-Maf promotes the differentiation of follicular helper T cells. Front. Immunol. 8, 480 (2017).
15. Buquet, A. T. et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular helper T cells and Th-17 cells. Nat. Immunol. 10, 167–175 (2009).
16. Perez-Mazilah, D. et al. Follicular helper T cells are essential for the elimination of plasmid-based infection. EBioMedicine 24, 216–230 (2017).
17. Ma, W., Noble, W. S. & Bailey, T. L. Motif-based analysis of large nucleotide data sets using MEME-ChIP . Nat. Protoc. 9, 1428–1450 (2014).
18. Chuang, L. S., Ito, K. & Ito, Y. RUNX family: regulation and diversification of thymus development through interacting proteins. Int. J. Cancer 132, 1260–1271 (2013).
19. Wang, S. et al. Target analysis by integration of transcriptome and ChIP-seq data with BETa. Nat. Protoc. 8, 2502–2515 (2013).
20. Baeks, Goldstein, & Hager, L. V. Bivariant genomic footprinting detects changes in transcription factor activity. Cell Rep. 19, 1710–1722 (2017).
21. Djuricic, I. M. et al. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in Th helper type 1 cells. Nat. Immunol. 8, 145–153 (2007).
22. Kataoka, K., Noda, M. & Nishizawa, M. Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and forms heterodimers with both Fos and Jun. Mol. Cell. Biol. 14, 700–712 (1994).
23. Lin, C. C. et al. Blhleii6 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation. Nat. Commun. 5, 3531 (2014).
24. Muller, M. R. & Rao, A. NFAT, immunity and cancer: a transcription factor comes of age. Nat. Rev. Immunol. 10, 645–656 (2010).
25. Webster, K. E. et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751–760 (2009).
26. Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunology 26, 371–381 (2007).

Acknowledgements
We thank R.A. Flavell (Yale University) for Foxp3RFP IL-10GFP mice; M. Sieweke and C. Birchmeier (Max Delbrück Centre for Molecular Medicine) for Maf6 mice; G. Trinchieri (Wistar Institute) for anti-IL-12p40 (C17:8.20); The Francis Crick Institute, Biological Services for breeding and maintenance of the mice; the Advanced Sequencing
Author contributions
L.G. co-designed the study with A.O.G., executed the experiments, interpreted and analyzed the data, and co-wrote the paper with A.O.G.; M.A.-M. analyzed the ATAC-seq, ChIP-seq and RNA-seq data and contributed to the writing of the paper; R.L. interpreted and analyzed the RNA-seq data and contributed to the writing of the paper; L.S.C. executed and helped design the in vitro experiments with c-Maf-deficient and control CD4+ T cells and analyzed the data; J.S. and C.H. helped execute and interpret malaria experiments; D.P.-M. contributed data for Supplementary Fig. 3; C.W. helped execute EAE experiments; Y.K. and M.W. helped execute and interpret allergy experiments; K.P. performed early RNA-seq analysis; X.W. executed the genetics for obtaining Cd4-cre×Maffl/fl mice and designed and performed all screening and quality control; L.B. performed processing and troubleshooting for RNA-seq analysis; H.W. constructed Maf fl/fl mice and provided feedback on the study; M.H.S. provided feedback and suggestions for the study; G.E. supervised analysis of early RNA-seq data; J.B. and V.M. provided advice and input on the ATAC-seq analysis; J.L. provided expertise for the malaria model and feedback on the study; N.M.L. provided advice and input on the RNA-seq analysis and directed the integrated analysis of ATAC-seq, ChIP-seq and RNA-seq; and A.O.G. co-designed the study with L.G., interpreted and analyzed the data, and co-wrote the paper with L.G.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41590-018-0083-5.

Reprints and permissions information is available at www.nature.com/reprints.

Correspondence and requests for materials should be addressed to A.O.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Experimental autoimmune encephalomyelitis (EAE) disease model. EAE was induced by immunization of mice (male or female) subcutaneously with 250 μg MOG35-55 peptide (Cambridge Research Biochemicals) emulsified in complete Freund's adjuvant containing 2 µg heat-killed M. tuberculosis H37RA (Difco) in 0.5 ml of saline. Mice were monitored daily for signs of clinical disease (body weight and clinical score) were taken daily, and results were calculated relative to the baseline at day 0. Disease severity scores were as follows: no paralysis = 0; flaccid tail; 1: impaired righting reflex and/or gait; 2: partial hindlimb paralysis; 3: complete hindlimb paralysis. For RNA-seq and ATAC-seq, CNS cells were isolated by Percoll gradient and purified from peripheral blood samples on day 10 after immunization, with 200 ng pertussis toxin (Calbiochem) intraperitoneally. Measurements of clinical pathology (body weight and clinical score) were taken daily, and results were calculated relative to the baseline at day 0. Disease severity scores were as follows: no paralysis = 0; flaccid tail; 1: impaired righting reflex and/or gait; 2: partial hindlimb paralysis; 3: complete hindlimb paralysis.

Flow cytometry and staining of intracellular cytokines and TFs for in vitro differentiated helper T cells. After differentiation, T cells were re-stimulated with anti-CD3 and anti-CD28 at 2 µg/ml each (both identified above) or with PDBU (Sigma-Aldrich) and ionomycin (Calbiochem) at 500 ng/ml each (T17, for 4 h, with brefeldin A (10 µg/ml, Sigma-Aldrich) added for the final 2 h or 4 h of culture respectively). Surface markers were stained intracellularly with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). For intracellular cytokine detection, cells were fixed with 2% formaldehyde, permeabilized with permeabilization buffer (eBioscience) and stained with the following: anti-IL-2 (11B11) PE, anti-IFN-γ (XMG1.2) PE-Cy7 and anti-IL-4 (GK1.5) FITC (all from BioLegend). For staining of Foxp3 and c-Maf, cells were fixed with Fixation/Permeabilization buffers and were stained with anti-Foxp3 (FJK-16S) PE or anti-c-Maf (SYM6IE) PerCP-eFluor 710 with isotype-matched control antibody IgG2bK (BMG2) eFluor 710 (all from eBioscience).

Intracellular cytokine staining of ex vivo cells. For the malaria model, spleen cells were isolated on day 12 after infection and were restimulated with 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h, with Golgi Plug (BD) added for the final 2 h of culture. Cells were then pretreated with anti-CD16/32 (2.4G2) (BD) and surface stained in PBS with anti-CD4 (RM4-5) BV605, anti-CD8 (53-6.7) BV510, anti-CD3 (17A2) APC-Cy7 and Zimbabua (all from BioLegend). After surface staining, cells were fixed with Fixation/Permeabilization buffers with anti-IL-10 (JES-516E3) FITC and anti-IFN-γ (XM1.2) PE-Cy7 (both from eBioscience). T cell staining was carried out as previously described.

For the EAE model, cells were isolated from spinal cords and brains on day 16 after immunization with Pecoll and were restimulated with 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h, with brefeldin A (10 µg/ml, Sigma-Aldrich) added for the final 3 h of culture. Cells were then pretreated with 10 µg/ml anti-CD16/32 (identified above) and surface stained in PBS with anti-CD45.2 (104) PE (eBioscience), anti-CD3 (17A2) BV785 and anti-CD45.1 (RM4-5) BV605 (BioLegend), together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). After surface staining, cells were fixed with 2% formaldehyde, permeabilized with permeabilization buffer and stained intracellularly with anti-IL-17A (eBi17B7) FITC, anti-IFN-γ (XM1.2) PE-Cy7 (both from eBioscience). T cell staining was carried out as previously described.

RNA extraction and pre-processing for RNA-seq. RNA from in vivo and ex vivo CD4+ T cells was extracted using the RNeasy Mini Kit according to the manufacturer's instructions (Qiagen). RNA-seq libraries were made with a TruSeq RNA Sample Preparation Kit V2 according to the manufacturer's instructions (for EAE, SMARTer Ultra Low Input RNA Kit v3 was used to generate CDNA that was then fragmented on Covaris S2 200 bp before the generation of libraries using a NuGen Ovation ultralow kit) and was sequenced using the HiSeq 2500 System with single-end read lengths of 50 bp, depth 27–65 million reads per sample (Illumina). Alignment of reads to the mouse transcriptome (mm10) and absolute quantification of the genes was performed in Strand NGS (version 2.0) with default parameters (95% identity, max 5% gaps, 1 read only if duplicated, ignoring reads

References
with more than five matches), guided by RefSeq annotations (2013.04.01) (in vitro helper T cells and ex vivo T cells) or Ensembl (2014.04.01) (ex vivo CD4+ T cells from the malaria, HDM allergy and EAE models). Further information on data processing is provided in the Supplementary Data.

**Quantitative RT-PCR.** RNA was extracted using RNAeasy microkit (Qiagen) and was reverse-transcribed into cDNA using a High Capacity Reverse Transcription kit (Applied Biosystems) according to the manufacturer’s instructions, followed by RNaseH (Promega) treatment for 30 min at 37 °C. cDNA was analyzed for the expression of the following factors on a 7900HT ABI or Q53 real-time PCR system (Applied Biosystems) with the following TaqMan primer probes (all from Applied Biosystems): mouse *Maf*, Mm 02581355_s1; *Il10*, Mm00439616_m1; *Tbx21*, Mm00450960_m1; *Ifng*, Mm01168134_m1; *Gata3*, Mm00484683_m1; *Il4*, Mm00445260_m1; *Rorc*, Mm01261019_g1; *Il17a*, Mm00439619_m1; *Foxp3*, Mm 00475162_m1; *Il2*, Mm 00434256_m1; and *Il2ra*, Mm 01340213_m1. The comparative threshold cycle method with *Hprt1*, Mm03024075_m1 as an internal control was used for the normalization of target-gene expression.

**ATAC-seq.** Samples were prepared as described previously32, with the transposition reaction carried out for 1 h and 30 min at 37 °C and subsequent PCR amplification for 12 cycles. For the EAE model, 25,000 cells were used and the transposition reaction was scaled down accordingly in a reaction volume of 25 μl. Further information on data processing is provided in the Supplementary Data.

**Statistical analysis.** GraphPad Prism Version 6 was used to perform experimental statistical analysis. The statistical significance of differences between data groups was determined by an unpaired, two-tailed Student’s *t*-test or two-tailed Mann-Whitney test where applicable at the 95% confidence level. For linear regression, correlation coefficients of determination and *P* values were calculated using the mean value of biological replicates. All sequencing data analyses were performed with the R statistical package version 3.3.1 (2016) and Bioconductor libraries version 3.3 unless otherwise stated (more information is provided in the Supplementary Data). Exact *n* values and error bars used are provided in the figure legends.

**Reporting Summary.** Further information on experimental design is available in the Nature Research Reporting Summary.

**Data availability statement.** The materials, data, code and any associated protocols that support the findings of this study are available from the corresponding author upon request. The RNA-seq and ATAC-seq datasets have been deposited in the Gene Expression Omnibus database under accession number GSE106464.

**References**
47. Kamanaka, M. et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. *Immunity* 25, 941–952 (2006).
48. Wende, H. et al. The transcription factor c-Maf controls touch receptor development and function. *Science* 335, 1373–1376 (2012).
49. Lee, P. P. et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. *Immunity* 15, 763–774 (2001).
50. Kaji, T. et al. Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. *J. Exp. Med.* 209, 2079–2097 (2012).
51. Freitas do Rosario, A. P. et al. Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to *Plasmodium chabaudi* AS despite persistence of B cell memory and circulating antibody. *J. Immunol.* 181, 8344–8355 (2008).
52. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat. Methods* 10, 1213–1218 (2013).
Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

1. Sample size
   - Describe how sample size was determined.
   - Animal sample size estimates were determined using previous studies and/or pilot studies using 4-5 animals per group and guided by the 3R principle.

2. Data exclusions
   - Describe any data exclusions.
   - No data exclusions were performed.

3. Replication
   - Describe the measures taken to verify the reproducibility of the experimental findings.
   - Unless otherwise stated, experimental replicates were included in analysis e.g. in RNA-Seq and ATAC-Seq analysis with appropriate statistical methods applied. Where representative data were shown, the experimental findings were reproduced with similar results.

4. Randomization
   - Describe how samples/organisms/participants were allocated into experimental groups.
   - Randomization was not carried out in this study. Animals were age and sex matched between experimental groups in order to account for covariates.

5. Blinding
   - Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
   - Blinding was performed during bioinformatic data analysis, using using unsupervised methods to identify differences in transcriptomic and genomic profiles. Blinding was not performed during data collection.

Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.

6. Statistical parameters
   - For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
   - n/a
     - Confirmed
     - The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
     - A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
     - A statement indicating how many times each experiment was replicated
     - The statistical test(s) used and whether they are one- or two-sided
     - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
     - A description of any assumptions or corrections, such as an adjustment for multiple comparisons
     - Test values indicating whether an effect is present
     - Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
     - A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
     - Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)

See the web collection on statistics for biologists for further resources and guidance.
7. Software

Describe the software used to analyze the data in this study.

Flow Cytometry:
Depending on the cytometer, data was collected using either Diva or BD FACSuite™ (BD LSR II, BD LSRFortessa™, BD Fusion or BD FACSD®) or Summit (MoFloTM XDP) Softwares. All data were analysed using FlowJo software (Treestar).

Histology:
OlyVIA software was used to view and score histology slides.

RNA-Seq:
For in vitro differentiated CD4+ T cell analysis, alignment of reads to the mouse transcriptome (mm10) and absolute quantification of the genes was performed in Strand NGS (version 2.0) with default parameters (95% identity, max 5% gaps, 1 read only if duplicated, ignoring reads with more than 5 matches), guided by RefSeq annotations (2013.04.01) (in vitro TH cells) or Ensembl (2014.04.01) (ex vivo CD4+ T cells). For ex vivo CD4+ T cell analysis, all analyses were performed with the R statistical package version 3.3.1 (2016) and Bioconductor libraries version 3.3. Proportional Venn diagrams were generated using eulerAPE webtool. Ingenuity Pathway Analysis (IPA) (QIAGEN Redwood City, www.qiagen.com/ingenuity) was used for gene family annotation and to obtain gene-gene interactions used to generate networks, which were then visualized with Cytoscape (version 3.4.0).

ATAC-Seq:
FastQC_0.11.5: for overall quality assessment
Skewer 0.2.2: sequencing quality control
IGV_2.3.97: genome browser visual inspection of ATAC-seq peaks in BED format
SAMtools 1.3.1 for alignment QC (discarded alignments with a mapQ < 30)
BWA-MEM: map pair-end reads to mm10
BEDTools 2.26.0: convert alignments from bam to bed format
Awk: command line tool. Used to remove alignments done to mitochondrial DNA, shift reads in the forward strand by + 4bp or reverse strand by -5 bp, and to remove fragments with a size >99bp.
MACS2 2.1.1: peak-calling
Diffbind 2.0.2: peak read quantification to test for differential changes in chromatin accessibility.
BagFoot: test for differential TF activity based on changes in Tn5 insertions on motif matching sites.
DeepTools 2.4.2: bamCoverage command to retrieve RPKM normalised
IGV_2.3.97: genome browser visual inspection of ATAC-seq peaks in BED format
R statistical software for data integration and visualization.

ChIP-Seq:
Trimmomatic 0.36: sequencing quality based trimming (parameters HEADCROP:2 TRAILING:25 MINLEN:26)
Bowtie 1.1.2: map single-end reads (parameters y –m2 --best --strata -S)
BEDTools 2.26.0: convert alignments from bam to bed format
MACS2 2.1.1: peak-calling
IGV_2.3.97: genome browser visual inspection of ChIP-seq peaks in BED format
R statistical software for data integration and visualization.

Other graphs and statistics:
GraphPad Prism Version 6 was used to plot bar graphs, box and whisker graphs and line graphs as well as to perform experimental statistical analysis.

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
### 9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

**Antibodies used in this study are as follows:**

**Flow cytometry:**

**eBioscience:**

| Name / Clone name / Catalog no. / Lot no. (most recent lot no.) / dilution factor or concentration |
|---|
| **CD4 eFluor 450 / RM4-5 / 48-0042-82 / E08484-1634 / 1:200** |
| **CD4 PE / RM4-5 / 12-0042-83 / E012640 / 1:200** |
| **CD2L PECy7 / MEL-14 / 25-0621-82 / E07577-1633 / 1:400** |
| **CD44 PE / IM7 / 12-0442-82 / E01240-1630 / 1:400** |
| **CD8 FITC / 53-6.7 / 11-0081-85 / E00116-1634 / 1:100** |
| **CD25 APC / PC61.5 / 17-0251-82 / E07106-1634 / 1:100** |
| **CD4 APC eFluor 780 / RM4-5 / 47-0042-82 / 42788618 / 1:100** |
| **Ter-119 / TER-119 / 14-5921-81 / 04582-1630 / 1:50** |
| **MHCII / M5/114.15.2 / 14-5321-85 / 4289851 / 1:50** |
| **CD11b FITC / M1/70 / 11-0112-85 / E016381 / 1:100** |
| **CD45.2 PE / 104 / 12-0454-81 / E01253-1633 / 1:200** |
| **CD3 APC / 145-2C11 / 17-0031-82 / 4283668 / 1:100** |
| **IL-17A FITC / eBi17B7 / 11-7177-81 / E00850-1632 / 1:300** |
| **Foxp3 PE / FJK-16S / 12-5773-82 / E01764-1640 / 1:200** |
| **IL-4 PE / 11B11 / 12-7041-82 / E01764-1640 / 1:200** |
| **CD4 APC eFluor 780 / RM4-5 / 47-0042-82 / E08484-1634 / 1:200** |

**BioLegend:**

| Name / Clone name / Catalog no. / Lot no. (most recent lot no.) / dilution factor or concentration |
|---|
| **CD4 BV605 / RM4-5 / 100548 / B180158 / 1:100** |
| **CD8 BV650 / 53-6.7 / 100741 / B175409 / 1:100** |
| **CD3 BV785 / 17A2 / 100231 / B177193 / 1:400** |
| **CD3 APCCy7 / 145-2C11 / 100329 / B168040 / 1:100** |
| **CD44 FICT / IM7 / 45-0442-82 / E08334-1634 / 1:100** |
| **IL-4 PECy7 / 11B11 / 25-7041-82 / 4314701 / 1:200** |
| **CD4 APCcoy5.5 / 145-2C11 / 45-0031-82 / E08288-1637 / 1:200** |

**BD:**

| Name / Clone name / Catalog no. / Lot no. (most recent lot no.) / dilution factor or concentration |
|---|
| **IFNg PECy7 / XMG1.2 / 557649 / 02121 / 1:800** |
| **CD4 BD Horizon V500 / RM4-5 / 568782 / 4278618 / 1:400** |
| **CD16/32 purified / 2.4G2 / 553142 / 3113814 / 1:500** |
| **CXCR5 (CD185) Biotin / 2G8 / 561271 / 1 in 200** |
| **CCR7 e450 / C17.8.20 / 551960 / 4318735 / 1:50** |

All flow cytometry antibodies were validated by the manufacturer.

**Cell culture:**

**Harlan, custom order:**

- **Anti-CD3 / 145-2C11 / 2 or 5 ug/ml**
- **Anti-CD28 / 37.51 / 2 or 10 ug/ml**
- **Anti-ifNg / XMG1.2 / 10ug/ml**
- **Anti-CD16/32 / 24G2 / 10ug/ml**

**Gift antibodies from DNAX:**

- **Anti-B220 / RA3-6A2 / 10ug/ml**
- **Anti-CD8 / C291.2.43 / 10ug/ml**
- **Anti-IL-6 / MP5-20F3 / 10ug/ml**
- **Anti-TGFb / 1D11.16 / 10ug/ml**

**Gift antibody from Dr. G. Trinchieri**

- **Anti-IL-12p40 / C17.8.20 / 10ug/ml**

Cell culture antibodies were certified for cell culture by the provider.
10. Eukaryotic cell lines
   a. State the source of each eukaryotic cell line used. Cell lines were not used in this study.
   b. Describe the method of cell line authentication used. Cell lines were not used in this study.
   c. Report whether the cell lines were tested for mycoplasma contamination. Cell lines were not used in this study.
   d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use. Cell lines were not used in this study.

Animals and human research participants

Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines

11. Description of research animals
   Provide all relevant details on animals and/or animal-derived materials used in the study.
   All mice were bred and maintained under specific pathogen-free conditions at The Francis Crick Institute, Mill Hill laboratory according to the Home Office UK Animals (Scientific Procedures) Act 1986 and mostly used at 8–16 weeks of age. C57BL/6 (females) wild-type mice were bred in-house Foxp3RFP IL-10GFP (females) were provided by R.A. Flavell. C-Maffl/fl mice provided by M. Sieweke and C. Birchmeier, were backcrossed to C57Bl/6 mice for ten generations and subsequently crossed to CD4Cre mice to generate c-Maffl/flCD4Cre mice, with c-Maffl/fl mice used as controls (malaria – males, HDM allergy – females, EAE – either males or females). Bcl6fl/fl were provided by T. Takemori and crossed to CD4Cre to generate Bcl6fl/flCD4Cre mice (female). All animal experiments were carried out in accordance with UK Home Office regulations (project licenses: malaria, 80/2358; HDM allergy, 80/2506; EAE, 70/7643) and were approved by The Francis Crick Institute Ethical Review Panel.

Policy information about studies involving human research participants

12. Description of human research participants
   Describe the covariate-relevant population characteristics of the human research participants.
   This study does not involve human participants.
Flow Cytometry Reporting Summary

Form fields will expand as needed. Please do not leave fields blank.

Data presentation

For all flow cytometry data, confirm that:

1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
3. All plots are contour plots with outliers or pseudocolor plots.
4. A numerical value for number of cells or percentage (with statistics) is provided.

Methodological details

5. Describe the sample preparation.

Figure 1:
Naive CD4+CD62L+CD44loCD25- T cells were purified from C57BL/6 mouse spleens by negative enrichment of CD4+ T cells, sorted on a MoFloTM XDP cytometer (Beckman Coulter) using CD4 e450, CD62L PECy7, CD44 PE and CD25 APC antibodies (all eBioscience) and differentiated in vitro under different TH conditions. Treg cells were sorted from IL-10GFPFoxp3RRFP dual-reporter mouse spleens directly ex vivo by negative enrichment of CD4+ T cells and sorting of CD4+ (CD4 APCe780, eBioscience) Foxp3RRFP+IL-10GFP- or Foxp3RRFP+IL-10GFP+ cells. After differentiation, T cells were re-stimulated with anti-CD3 and anti-CD28 at 2 µg/ml each (all TH but TH17) or PDBU (Sigma-Aldrich) and Ionomycin (Calbiochem) at 500 ng/ml each (TH17) for 4 hours, with Brefeldin A (10 µg/ml, Sigma-Aldrich) added for the last 2 or 4 hours of culture, respectively. Surface markers were stained in PBS together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). For intracellular cytokine detection, cells were fixed with 2% formaldehyde, permeabilized with permeabilization buffer (eBioscience) and stained with: anti-IL-2 APC-Cy7 (BD), anti-IFNg PECy7 (BD) and anti-IL-4 PE, anti-IL17A FITC (eBioscience). For Foxp3 staining, cells were fixed with Fixation/Permeabilization buffers and stained with anti-Foxp3 PE (eBioscience).

Supplementary Figure 1:
Naive CD4+CD62L+CD44loCD25- T cells were purified from C57BL/6 mouse spleens by negative enrichment of CD4+ T cells, sorted on a MoFloTM XDP cytometer (Beckman Coulter) using CD4 e450, CD62L PECy7, CD44 PE and CD25 APC antibodies (all eBioscience) and differentiated in vitro under different TH conditions. On day three of culture, T cells were stained in PBS with CD4 (BD Horizon V500, BD) together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). For c-Maf staining, cells were fixed with Fixation/Permeabilization buffers and stained with c-Maf PerCP-eFluor 710 or isotype control antibodies (eBioscience).

Figures 3, 4 and 6 and accompanying Supplementary Figures:
CD4+ T cell isolation from the different disease models for subsequent RNA-Seq and ATAC-Seq analysis:
Malaria: CD4+ T cells were enriched by negative selection from individual spleens on day 7 post infection (3 individual mice c-Maffl/fl and c-Maffl/fl CD4Cre) and Ter119-CD3+CD4+ T cells (Ter119- APCy7, CD3 APC, CD4 e450) were sorted on MoFloTM XDP MoFloTM XDP (Beckman Coulter) or BD Fusion cytometers.
HDM allergy: CD4+ T cells were enriched by positive selection (Miltenyi Biotech) from perfused lungs on day 25 (pooled from at least 5 c-Maffl/fl or c-Maffl/fl CD4Cre mice) following a Percoll gradient separation and CD3+CD4+CD44+ (CD3 APC, CD4 e450 and CD44 PE, eBioscience) T cells were sorted on MoFloTM XDP.
EAE: CNS cells were enriched by Percoll gradient from perfused brains and spinal cords (pooled from at least 10 c-Maffl/fl or c-Maffl/fl CD4Cre mice) on day 14-16 post immunization and CD45.2+CD3+CD4+ (CD45.2 PE, CD4 e450, CD3 APC) T cells were sorted on MoFloTM XDP cytometer.

Figure 5:
CD4+ T cell intracellular cytokine staining:
Malaria; spleen cells were isolated on day 12 post infection and restimulated with 50 ng/ml PMA and 500 ng/ml Ionomycin (Sigma-Aldrich) for 4 hours, with Golgi Plug (BD) added for the last 2 hours of culture. Cells were then pretreated with anti-CD16/32 (BD) and surface stained in PBS with CD4 BV605, CD8 BV650, CD3 APC/Cy7 antibodies and Zombie Aqua live/dead dye (Biolegend). After surface staining, cells were fixed with Fixation buffer followed by permeabilization in Perm Buffer (Biolegend) and stained intracellularly with IL-10 FITC and IFNγ PECy7 antibodies (eBioscience). For TFH cells, spleen cells were isolated on day 14 post infection and restimulated with 50 ng/ml PMA and 500 ng/ml Ionomycin (Sigma-Aldrich) for 5 hours, with Brefeldin A (10 ug/ml, Sigma-Aldrich). Cells were then pretreated for 15 mins with anti-CD16/32 (BD) and first surface stained with anti-CXCR5-Bio (BD) in IMDM for 35 mins at 37C, washed and then stained in PBS with CD4 APC/Cy7, CD3 PB, CD44 PerCP-Cy5.5, PD-1 PECy7 antibodies, Streptavidin APC (Biolegend) and Zombie Aqua live/dead dye (Invitrogen) for 30 mins at 4C. After surface staining, cells were fixed with 2% paraformaldehyde for 10 mins followed by permeabilization in Perm Buffer (BD) and stained intracellularly with anti-IL-10 FITC and IL-10 APC antibodies (eBioscience).

HDM allergy; lung cells were isolated from the right lower lobe on day 25 using Percoll and restimulated with 50 ng/ml PMA and 1 mg/ml Ionomycin (Sigma-Aldrich) and Golgi Stop and Plug (BD) for 6 hours. Cell were then surface stained in PBS with CD3 APC-Fluor780, CD4 eFluor450, CD44 PerCpCy5.5 antibodies (eBioscience) in the presence of anti-CD16/32 together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). After surface staining, cells were fixed with 2% formaldehyde, permeabilized with permeabilization buffer and stained intracellularly with IL-4 PECy7 and IL-10 APC antibodies (eBioscience).

EAE; cells were isolated from spinal cords and brains on day 16 post immunization using Percoll and restimulated with 50ng/ml PMA and 500 ng/ml Ionomycin for 4 hours, with Brefeldin A (10 ug/ml, Sigma-Aldrich) added for the last 3 hours of culture. Cells were then pretreated with anti-CD16/32 (10 ug/ml, Harlan) and surface stained in PBS with CD45.2 PE (eBioscience), CD3 BV785 and CD4 BV605 (Biolegend) antibodies together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). After surface staining, cells were fixed with intranuclear Fixation/Permeabilization buffers (eBioscience) and stained with IL-17A FITC, Foxp3 PE (eBioscience) and IFNγ PECy7 (BD) antibodies.

6. Identify the instrument used for data collection.

Samples to be analysed were acquired on BD LSR II, BD LSRFortessaTM or BD FACSVerse (Beckton Dickinson) cytometers. Ex vivo CD4+ T cells were sorted on MoFloTM XDP (Beckman Coulter) or BD Fusion cytometers.

7. Describe the software used to collect and analyze the flow cytometry data.

Depending on the cytometer, data was collected using either Diva or BD FACSuiteTM (BD LSR II, BD LSRFortessaTM, BD Fusion or BD FACSVerse) or Summit (MoFloTM XDP) Softwares. All data were analysed using FlowJo software (Treestar).

8. Describe the abundance of the relevant cell populations within post-sort fractions.

Naïve CD4+CD62L+CD44loCD25- were routinely sorted to over 95% purity, using a purity mode setting. Ex vivo CD4+ T cells for RNA-Seq and ATAC-Seq studies were also sorted to over 95% purity.

9. Describe the gating strategy used.

For sorting of naïve CD4+CD62L+CD44loCD25-, cells were gated on lymphocytes in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+ T cells as defined by lack of PI staining in PI/CD4 eFluor 450 plot, followed by gating on CD8-CD25- cells in CD25 APC/CD8 FITC plot, followed by gating on CD62L+CD44lo cells in CD62L PECy7 / CD44 PE plot.

Ex vivo Treg cells were sorted as follows, cells were gated on lymphocytes in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+ T cells as defined by lack of dead cell
dye in LIVE/DEAD Fixable Violet/CD4 APC eFluor 780 plot, followed by gating on Foxp3RFP+IL-10GFP- or Foxp3RFP+IL-10GFP+ cells.

For analysis of intracellular cytokines or proteins after in vitro differentiation, cells were gated on live CD4+ T cells as follows: lymphocytes were gated in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+ T cells as defined by lack of dead cell dye in LIVE/DEAD Fixable Blue/CD4 BD Horizon V500 plot.

For analysis of intracellular cytokines or proteins after in vitro differentiation, cells were gated on live CD4+ T cells as follows: lymphocytes were gated in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+ T cells as defined by lack of dead cell dye in LIVE/DEAD Fixable Blue/CD4 BD Horizon V500 plot.

For sorting of CD4+ T cells from disease models ex vivo: Malaria: Cells were gated on lymphocytes in FSC/SSC gate, followed by exclusion of doublets in FSC-A/FSC-H parameters, followed by gating on live Ter119- T cells as defined by lack of PI staining in PI/Ter119 APCCy7 plot, followed by gating on CD3+CD4+ T cells in CD3 APC/CD4 eFluor 450 plot.

HDM: Cells were gated on lymphocytes in FSC/SSC gate, followed by exclusion of doublets in FSC-A/FSC-H parameters, followed by gating on live CD3+ T cells as defined by lack of PI staining in PI/CD3 APC plot, followed by gating on CD4+ T cells in CD4 eFluor 450/CD8 FITC plot, followed by gating on CD44+ cells in CD4 eFluor 450/CD44 PE plot.

EAE: Cells were gated on live lymphocytes in viability PI/FSC plot, followed by exclusion of doublets in both FSC-W/FSC-H and SSC-W/SSC-H parameters, followed by gating on CD45.2+ T cells in CD45.2 PE/CD11b FITC plot, followed by gating on CD3+CD4+ T cells in CD3 APC/CD4 eFluor 450 plot.

For analysis of intracellular cytokines ex vivo, cells were gated as follows: Malaria: Lymphocytes were gated in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+ T cells as defined by lack of dead cell dye in Zombie Aqua/CD3 APCCy7 plot, followed by gating on CD4+CD8- T cells in CD4 BV605/CD8 BV650 plot.

For TFH staining, Lymphocytes were gated in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+CD44hi T cells as defined by lack of dead cell dye in Zombie Aqua, further gating on CD3+CD4+ T cells in CD3PB/CD4 APCCy7 plot, CD44hi PerCpCy5.5+ cells and defining the percentage of IL-10 FITC+ in CXCR5+PD-1+, CXCR5+PD-1-, CXCR5-PD-1+ and CXCR5-PD-1- populations in a CXCR5 APC/PD-1 PECy7 plot.

HDM allergy: Lymphocytes were gated in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+ T cells as defined by lack of dead cell dye in LIVE/DEAD Fixable Blue/CD3 APCeFluor780 plot, followed by gating on CD4+CD44hi T cells in CD4 eFluor450/CD44 PerCpCy5.5 plot.

EAE: Lymphocytes were gated in FSC/SSC gate, followed by exclusion of doublets in both FSC-A/FSC-H and SSC-A/SSC-H parameters, followed by gating on live CD4+ T cells as defined by lack of dead cell dye in LIVE/DEAD Fixable Blue in a histogram, followed by gating on CD3+CD4+ T cells in CD3 PerCpCy5.5/CD4 V500 plot.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information. ☐
ChIP-seq Reporting Summary

Form fields will expand as needed. Please do not leave fields blank.

- **Data deposition**

  1. For all ChIP-seq data:
     a. Confirm that both raw and final processed data have been deposited in a public database such as GEO.
     b. Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

  2. Provide all relevant data deposition access links.
     The entry may remain private before publication.

     * GSE106464 is the reference Series for your publication:
       https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106464

     * This SuperSeries record provides access to all of your data and is the best accession to be quoted in any manuscript discussing the data.

     * You may also cite the SubSeries that are linked to GSE106464:
       (ATAC-seq) https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106461
       (RNA-seq in vivo) https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106462
       (RNA-seq in vitro) https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106463

  3. Provide a list of all files available in the database submission.

     **ATAC-Seq:**
     https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106461

     Sample name
     UNT_C57BL6_1
     MAL_cMaf_flfl_1
     MAL_cMaf_flfl_2
     MAL_cMaf_flfl_3
     MAL_cMaf_flfl_CD4Cre_1
     MAL_cMaf_flfl_CD4Cre_2
     MAL_cMaf_flfl_CD4Cre_3
     HDM_cMaf_flfl_1
     HDM_cMaf_flfl_2
     HDM_cMaf_flfl_3
     HDM_cMaf_flfl_CD4Cre_1
     HDM_cMaf_flfl_CD4Cre_2
     HDM_cMaf_flfl_CD4Cre_3
     EAE_cMaf_flfl_1
     EAE_cMaf_flfl_2
     EAE_cMaf_flfl_3
     EAE_cMaf_flfl_CD4Cre_1
     EAE_cMaf_flfl_CD4Cre_2
     EAE_cMaf_flfl_CD4Cre_3

     raw file
     ATAC_UNT_C57BL6_1_GAN719A7_R1_001.fastq.gz
     ATAC_MAL_cMaf_flfl_1_GAN719A3_S1_L001_R1_001.fastq.gz
     ATAC_MAL_cMaf_flfl_2_GAB139A17_S6_L006_R1_001.fastq.gz
     ATAC_MAL_cMaf_flfl_3_GAB139A18_S7_L007_R1_001.fastq.gz
     ATAC_MAL_cMaf_flfl_CD4Cre_1_GAN719A11_S7_L007_R1_001.fastq.gz
     ATAC_MAL_cMaf_flfl_CD4Cre_2_GAN719A12_S8_L008_R1_001.fastq.gz
     ATAC_MAL_cMaf_flfl_CD4Cre_3_GAN719A4_S2_L002_R1_001.fastq.gz
     ATAC_HDM_cMaf_flfl_1_GAN719A15_S5_L007_R1_001.fastq.gz
     ATAC_HDM_cMaf_flfl_2_GAN719A17_S2_L002_R1_001.fastq.gz
     ATAC_HDM_cMaf_flfl_3_GAN719A5_S3_L003_R1_001.fastq.gz
ATAC_HDM_cMaf_flfl_CD4Cre_1_GAN719A18_S3_L003_R1_001.fastq.gz
ATAC_HDM_cMaf_flfl_CD4Cre_2_GAN719A6_S4_L004_R1_001.fastq.gz
ATAC_HDM_cMaf_flfl_CD4Cre_3_GAB139A23_S37_L008_R1_001.fastq.gz
ATAC_EAE_cMaf_flfl_1_GAB139A16_S5_L005_R1_001.fastq.gz
ATAC_EAE_cMaf_flfl_2_GAB139A20_S34_L005_R1_001.fastq.gz
ATAC_EAE_cMaf_flfl_3_GAB139A22_S36_L007_R1_001.fastq.gz
ATAC_EAE_cMaf_flfl_CD4Cre_1_GAB139A15_S4_L004_R1_001.fastq.gz
ATAC_EAE_cMaf_flfl_CD4Cre_2_GAB139A19_S33_L004_R1_001.fastq.gz
ATAC_EAE_cMaf_flfl_CD4Cre_3_GAB139A21_S35_L006_R1_001.fastq.gz

raw file
ATAC_UNT_C57BL6_1_GAN719A7_R2_001.fastq.gz
ATAC_MAL_cMaf_flfl_1_GAN719A3_S1_L001_R2_001.fastq.gz
ATAC_MAL_cMaf_flfl_2_GAB139A17_S6_L006_R2_001.fastq.gz
ATAC_MAL_cMaf_flfl_3_GAB139A18_S7_L007_R2_001.fastq.gz
ATAC_MAL_cMaf_flfl_CD4Cre_1_GAN719A11_S7_L007_R2_001.fastq.gz
ATAC_MAL_cMaf_flfl_CD4Cre_2_GAN719A12_S8_L008_R2_001.fastq.gz
ATAC_MAL_cMaf_flfl_CD4Cre_3_GAN719A4_S2_L002_R2_001.fastq.gz
ATAC_HDM_cMaf_flfl_1_GAN719A15_S5_L007_R2_001.fastq.gz
ATAC_HDM_cMaf_flfl_2_GAN719A17_S2_L002_R2_001.fastq.gz
ATAC_HDM_cMaf_flfl_3_GAN719A5_S3_L003_R2_001.fastq.gz
ATAC_HDM_cMaf_flfl_CD4Cre_1_GAN719A18_S3_L003_R2_001.fastq.gz
ATAC_HDM_cMaf_flfl_CD4Cre_2_GAN719A6_S4_L004_R2_001.fastq.gz
ATAC_HDM_cMaf_flfl_CD4Cre_3_GAB139A23_S37_L008_R2_001.fastq.gz
ATAC_EAE_cMaf_flfl_1_GAB139A16_S5_L005_R2_001.fastq.gz
ATAC_EAE_cMaf_flfl_2_GAB139A20_S34_L005_R2_001.fastq.gz
ATAC_EAE_cMaf_flfl_3_GAB139A22_S36_L007_R2_001.fastq.gz
ATAC_EAE_cMaf_flfl_CD4Cre_1_GAB139A15_S4_L004_R2_001.fastq.gz
ATAC_EAE_cMaf_flfl_CD4Cre_2_GAB139A19_S33_L004_R2_001.fastq.gz
ATAC_EAE_cMaf_flfl_CD4Cre_3_GAB139A21_S35_L006_R2_001.fastq.gz

processed data file
ATAC_UNT_C57BL6_1_GAN719A7_bwa_dedup_noMt_shifted_rpkmbw
ATAC_MAL_cMaf_flfl_1_MALARIA_GAN719A3_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_MAL_cMaf_flfl_2_MALARIA_GAN719A21_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_MAL_cMaf_flfl_3_MALARIA_GAN719A22_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_MAL_cMaf_flfl_CD4Cre_1_MALARIA_GAN719A11_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_MAL_cMaf_flfl_CD4Cre_2_MALARIA_GAN719A12_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_MAL_cMaf_flfl_CD4Cre_3_MALARIA_GAN719A4_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_HDM_cMaf_flfl_1_HDM_GAN719A15_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_HDM_cMaf_flfl_2_HDM_GAN719A17_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_HDM_cMaf_flfl_3_HDM_GAN719A5_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_HDM_cMaf_flfl_CD4Cre_1_HDM_GAN719A18_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_HDM_cMaf_flfl_CD4Cre_2_HDM_GAN719A6_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_HDM_cMaf_flfl_CD4Cre_3_HDM_GAN719A27_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_EAE_cMaf_flfl_1_EAE_GAN719A20_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_EAE_cMaf_flfl_2_EAE_GAN719A24_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_EAE_cMaf_flfl_3_EAE_GAN719A26_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_EAE_cMaf_flfl_CD4Cre_1_EAE_GAN719A19_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
ATAC_EAE_cMaf_flfl_CD4Cre_2_EAE_GAN719A23_NoNucl_bwa_dedup_noMt_shifted_rpkmbw
fted_rpkm.bw
ATAC_EAE_cMaf_flfl_CD4Cre_3_EAE_GAN719A25_NoNucl_bwa_dedup_noMt_shi
ted_rpkm.bw

processed data file
ATAC_UNT_C57BL6_1_GAN719A7_peaks.narrowPeak
ATAC_MAL_cMaf_flfl_1_MALARIA_GAN719A3_NoNucl_peaks.narrowPeak
ATAC_MAL_cMaf_flfl_2_MALARIA_GAN719A21_NoNucl_peaks.narrowPeak
ATAC_MAL_cMaf_flfl_3_MALARIA_GAN719A22_NoNucl_peaks.narrowPeak
ATAC_MAL_cMaf_flfl_CD4Cre_1_MALARIA_GAN719A11_NoNucl_peaks.narrowPea
k
ATAC_MAL_cMaf_flfl_CD4Cre_2_MALARIA_GAN719A12_NoNucl_peaks.narrowPea
k
ATAC_MAL_cMaf_flfl_CD4Cre_3_MALARIA_GAN719A4_NoNucl_peaks.narrowPea
k
ATAC_HDM_cMaf_flfl_1_HDM_GAN719A15_NoNucl_peaks.narrowPeak
ATAC_HDM_cMaf_flfl_2_HDM_GAN719A17_NoNucl_peaks.narrowPeak
ATAC_HDM_cMaf_flfl_3_HDM_GAN719A5_NoNucl_peaks.narrowPeak
ATAC_HDM_cMaf_flfl_CD4Cre_1_HDM_GAN719A18_NoNucl_peaks.narrowPeak
ATAC_HDM_cMaf_flfl_CD4Cre_2_HDM_GAN719A6_NoNucl_peaks.narrowPeak
ATAC_HDM_cMaf_flfl_CD4Cre_3_HDM_GAN719A7_NoNucl_peaks.narrowPeak
ATAC_EAE_cMaf_flfl_1_EAE_GAN719A20_NoNucl_peaks.narrowPeak
ATAC_EAE_cMaf_flfl_2_EAE_GAN719A24_NoNucl_peaks.narrowPeak
ATAC_EAE_cMaf_flfl_3_EAE_GAN719A26_NoNucl_peaks.narrowPeak
ATAC_EAE_cMaf_flfl_CD4Cre_1_EAE_GAN719A19_NoNucl_peaks.narrowPeak
ATAC_EAE_cMaf_flfl_CD4Cre_2_EAE_GAN719A23_NoNucl_peaks.narrowPeak
ATAC_EAE_cMaf_flfl_CD4Cre_3_EAE_GAN719A25_NoNucl_peaks.narrowPeak

RNA-seq in vivo:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106462

Sample name
RNA_EAE_cMaf_flfl_1
RNA_EAE_cMaf_flfl_2
RNA_EAE_cMaf_flfl_3
RNA_EAE_cMaf_flfl_CD4Cre_1
RNA_EAE_cMaf_flfl_CD4Cre_2
RNA_EAE_cMaf_flfl_CD4Cre_3
RNA_HDM_cMaf_flfl_1
RNA_HDM_cMaf_flfl_2
RNA_HDM_cMaf_flfl_3
RNA_HDM_cMaf_flfl_CD4Cre_1
RNA_HDM_cMaf_flfl_CD4Cre_2
RNA_HDM_cMaf_flfl_CD4Cre_3
RNA_MAL_cMaf_flfl_1
RNA_MAL_cMaf_flfl_2
RNA_MAL_cMaf_flfl_3
RNA_MAL_cMaf_flfl_CD4Cre_1
RNA_MAL_cMaf_flfl_CD4Cre_2
RNA_MAL_cMaf_flfl_CD4Cre_3
RNA_UNT_cMaf_flfl_1
RNA_UNT_cMaf_flfl_2
RNA_UNT_cMaf_flfl_3

raw file
RNA_EAE_cMaf_flfl_1.fastq.gz
RNA_EAE_cMaf_flfl_2.fastq.gz
RNA_EAE_cMaf_flfl_3.fastq.gz
RNA_EAE_cMaf_flfl_CD4Cre_1.fastq.gz
RNA_EAE_cMaf_flfl_CD4Cre_2.fastq.gz
RNA_EAE_cMaf_flfl_CD4Cre_3.fastq.gz
RNA_HDM_cMaf_flfl_1.fastq.gz
RNA_HDM_cMaf_flfl_2.fastq.gz
RNA_HDM_cMaf_flfl_3.fastq.gz
RNA_HDM_cMaf_flfl_CD4Cre_1.fastq.gz
RNA_HDM_cMaf_flfl_CD4Cre_2.fastq.gz
RNA_HDM_cMaf_flfl_CD4Cre_3.fastq.gz
RNAseq in vitro:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106463

Sample name
FoxP3IL10neg_Ohr_BR1.TR1.Run1
FoxP3IL10neg_Ohr_BR2.TR1.Run1
FoxP3IL10neg_Ohr_BR3.TR1.Run1
FoxP3IL10pos_Ohr_BR1.TR1.Run1
FoxP3IL10pos_Ohr_BR2.TR1.Run1
FoxP3IL10pos_Ohr_BR3.TR1.Run1
Naive_0.5hr_BR1.TR1.Run1
Naive_0.5hr_BR2.TR1.Run1
Naive_0.5hr_BR2.TR2.Run1
Naive_0.5hr_BR2.TR3.Run1
Naive_Ohr_BR1.TR1.Run1
Naive_Ohr_BR1.TR1.Run2
Naive_Ohr_BR2.TR1.Run1
Naive_Ohr_BR2.TR2.Run1
Naive_Ohr_BR2.TR3.Run1
Naive_2hr_BR1.TR1.Run1
Naive_2hr_BR1.TR1.Run2
Naive_2hr_BR2.TR1.Run1
Naive_2hr_BR2.TR2.Run1
Naive_2hr_BR2.TR3.Run1
Naive_6hr_BR1.TR1.Run1
Naive_6hr_BR1.TR1.Run2
Naive_6hr_BR2.TR1.Run1
Naive_6hr_BR2.TR2.Run1
Naive_6hr_BR2.TR3.Run1
THO_0.5hr_BR1.TR1.Run1
THO_0.5hr_BR1.TR2.Run1
THO_0.5hr_BR1.TR3.Run1
TH0_0.5hr_BR2_TR1_Run1
TH0_0.5hr_BR2_TR2_Run1
TH0_0.5hr_BR2_TR3_Run1
TH0_0hr_BR1_TR1_Run1
TH0_0hr_BR1_TR2_Run1
TH0_0hr_BR1_TR3_Run1
TH0_0hr_BR2_TR1_Run1
TH0_0hr_BR2_TR2_Run1
TH0_0hr_BR2_TR3_Run1
TH0_2hr_BR1_TR1_Run1
TH0_2hr_BR1_TR2_Run1
TH0_2hr_BR1_TR3_Run1
TH0_2hr_BR2_TR1_Run1
TH0_2hr_BR2_TR2_Run1
TH0_2hr_BR2_TR3_Run1
TH0_6hr_BR1_TR1_Run1
TH0_6hr_BR1_TR2_Run1
TH0_6hr_BR1_TR3_Run1
TH0_6hr_BR2_TR1_Run1
TH0_6hr_BR2_TR2_Run1
TH0_6hr_BR2_TR3_Run1
TH0block_0.5hr_BR1_TR1_Run1
TH0block_0.5hr_BR1_TR1_Run2
TH0block_0.5hr_BR2_TR1_Run1
TH0block_0.5hr_BR2_TR1_Run2
TH0block_0hr_BR1_TR1_Run1
TH0block_0hr_BR1_TR1_Run2
TH0block_0hr_BR2_TR1_Run1
TH0block_0hr_BR2_TR1_Run2
TH0block_2hr_BR1_TR1_Run1
TH0block_2hr_BR1_TR1_Run2
TH0block_2hr_BR1_TR1_Run2
TH0block_2hr_BR1_TR1_Run2
TH0block_2hr_BR2_TR1_Run1
TH0block_2hr_BR3_TR1_Run1
TH0block_2hr_BR3_TR1_Run1
TH0block_6hr_BR1_TR1_Run1
TH0block_6hr_BR1_TR1_Run2
TH0block_6hr_BR2_TR1_Run1
TH0block_6hr_BR2_TR1_Run1
TH0block_6hr_BR2_TR1_Run1
TH0block_6hr_BR2_TR1_Run1
TH1_0.5hr_BR1_TR1_Run1
TH1_0.5hr_BR2_TR1_Run1
TH1_0.5hr_BR2_TR1_Run2
TH1_0hr_BR1_TR1_Run1
TH1_0hr_BR2_TR1_Run1
TH1_0hr_BR2_TR1_Run2
TH1_2hr_BR1_TR1_Run1
TH1_2hr_BR2_TR1_Run1
TH1_2hr_BR2_TR1_Run2
TH1_6hr_BR1_TR1_Run1
TH1_6hr_BR1_TR1_Run1
TH1_6hr_BR2_TR1_Run1
TH1_6hr_BR2_TR1_Run2
TH17_0.5hr_BR1_TR1_Run1
TH17_0.5hr_BR1_TR2_Run1
TH17_0.5hr_BR1_TR3_Run1
TH17_0.5hr_BR2_TR1_Run1
TH17_0.5hr_BR2_TR2_Run1
TH17_0.5hr_BR2_TR3_Run1
TH17_0hr_BR1_TR1_Run1
TH17_0hr_BR1_TR2_Run1
TH17_0hr_BR1_TR3_Run1
TH17_0hr_BR2_TR1_Run1
TH17_0hr_BR2_TR2_Run1
TH17_0hr_BR2_TR3_Run1
TH17_2hr_BR1_TR1_Run1
TH17_2hr_BR1_TR2_Run1
TH17_2hr_BR1_TR3_Run1
TH17_2hr_BR2_TR1_Run1
TH17_2hr_BR2_TR2_Run1
TH17_2hr_BR2_TR3_Run1
TH17_2hr_BR2_TR2_Run1
TH17_6hr_BR1_TR1_Run1
TH17_6hr_BR1_TR2_Run1
TH17_6hr_BR2_TR1_Run1
TH17_6hr_BR2_TR2_Run1
TH17_2hr_BR2_TR3_Run1
TH17_6hr_BR1_TR1_Run1
TH17_6hr_BR1_TR2_Run1
TH17_6hr_BR1_TR3_Run1
TH17_6hr_BR2_TR1_Run1
TH17_6hr_BR2_TR2_Run1
TH17_6hr_BR2_TR3_Run1
TH17L27_Ohr_BR1_TR1_Run1
TH17L27_Ohr_BR2_TR1_Run1
TH17L27_2hr_BR1_TR1_Run1
TH17L27_2hr_BR2_TR1_Run1
TH17L27_6hr_BR1_TR1_Run1
TH17L27_6hr_BR2_TR1_Run1
TH2_0.5hr_BR1_TR1_Run1
TH2_0.5hr_BR1_TR1_Run2
TH2_0.5hr_BR2_TR1_Run1
TH2_0.5hr_BR2_TR1_Run2
TH2_0hr_BR1_TR1_Run1
TH2_0hr_BR1_TR1_Run2
TH2_0hr_BR2_TR1_Run1
TH2_0hr_BR2_TR1_Run2
TH2_2hr_BR1_TR1_Run1
TH2_2hr_BR1_TR1_Run2
TH2_2hr_BR2_TR1_Run1
TH2_2hr_BR2_TR1_Run2
TH2_6hr_BR1_TR1_Run1
TH2_6hr_BR2_TR1_Run1
VitDex_0.5hr_BR1_TR1_Run1
VitDex_0.5hr_BR2_TR1_Run1
VitDex_0hr_BR1_TR1_Run1
VitDex_0hr_BR2_TR1_Run1
VitDex_2hr_BR1_TR1_Run1
VitDex_2hr_BR1_TR1_Run2
VitDex_6hr_BR1_TR1_Run1
VitDex_6hr_BR2_TR1_Run1
raw file
Foxp3IL10neg_Ohr_BR1_TR1_Run1.fastq.gz
Foxp3IL10neg_Ohr_BR2_TR1_Run1.fastq.gz
Foxp3IL10neg_Ohr_BR3_TR1_Run1.fastq.gz
Foxp3IL10pos_Ohr_BR1_TR1_Run1.fastq.gz
Foxp3IL10pos_Ohr_BR2_TR1_Run1.fastq.gz
Foxp3IL10pos_Ohr_BR3_TR1_Run1.fastq.gz
Naive_0.5hr_BR1_TR1_Run1.fastq.gz
Naive_0.5hr_BR2_TR1_Run1.fastq.gz
Naive_0.5hr_BR2_TR2_Run1.fastq.gz
Naive_0.5hr_BR2_TR3_Run1.fastq.gz
Naive_0hr_BR1_TR1_Run1.fastq.gz
Naive_0hr_BR1_TR1_Run2.fastq.gz
Naive_0hr_BR2_TR1_Run1.fastq.gz
Naive_0hr_BR2_TR2_Run1.fastq.gz
Naive_0hr_BR2_TR3_Run1.fastq.gz
Naive_2hr_BR1_TR1_Run1.fastq.gz
Naive_2hr_BR1_TR1_Run2.fastq.gz
Naive_2hr_BR2_TR1_Run1.fastq.gz
Naive_2hr_BR2_TR1_Run2.fastq.gz
Naive_6hr_BR1_TR1_Run1.fastq.gz
Naive_6hr_BR1_TR1_Run2.fastq.gz
Naive_6hr_BR2_TR1_Run1.fastq.gz
Naive_6hr_BR2_TR2_Run1.fastq.gz
Naive_6hr_BR2_TR3_Run1.fastq.gz
TH0_0.5hr_BR1_TR1_Run1.fastq.gz
TH0_0.5hr_BR1_TR2_Run1.fastq.gz
TH0_0.5hr_BR2_TR1_Run1.fastq.gz
TH0_0.5hr_BR2_TR2_Run1.fastq.gz
TH0_0.5hr_BR2_TR3_Run1.fastq.gz
TH0_0hr_BR1_TR1_Run1.fastq.gz
TH0_0hr_BR1_TR2_Run1.fastq.gz
TH0_0hr_BR1_TR3_Run1.fastq.gz
TH0_0hr_BR2_TR1_Run1.fastq.gz
TH0_0hr_BR2_TR2_Run1.fastq.gz
TH0_0hr_BR2_TR3_Run1.fastq.gz
TH0_2hr_BR1_TR1_Run1.fastq.gz
TH0_2hr_BR1_TR2_Run1.fastq.gz
TH0_2hr_BR1_TR3_Run1.fastq.gz
TH0_2hr_BR2_TR1_Run1.fastq.gz
TH0_2hr_BR2_TR2_Run1.fastq.gz
TH0_2hr_BR2_TR3_Run1.fastq.gz
TH0_6hr_BR1_TR1_Run1.fastq.gz
TH0_6hr_BR1_TR2_Run1.fastq.gz
TH0_6hr_BR1_TR3_Run1.fastq.gz
TH0_6hr_BR2_TR1_Run1.fastq.gz
TH0_6hr_BR2_TR2_Run1.fastq.gz
TH0_6hr_BR2_TR3_Run1.fastq.gz
TH0block_0.5hr_BR1_TR1_Run1.fastq.gz
TH0block_0.5hr_BR1_TR1_Run2.fastq.gz
TH0block_0.5hr_BR2_TR1_Run1.fastq.gz
TH0block_0.5hr_BR2_TR1_Run2.fastq.gz
TH0block_0hr_BR1_TR1_Run1.fastq.gz
TH0block_0hr_BR1_TR1_Run2.fastq.gz
TH0block_0hr_BR2_TR1_Run1.fastq.gz
TH0block_0hr_BR2_TR1_Run2.fastq.gz
TH0block_2hr_BR1_TR1_Run1.fastq.gz
TH0block_2hr_BR1_TR1_Run2.fastq.gz
TH0block_2hr_BR2_TR1_Run1.fastq.gz
TH0block_2hr_BR2_TR1_Run2.fastq.gz
TH0block_6hr_BR1_TR1_Run1.fastq.gz
TH0block_6hr_BR1_TR1_Run2.fastq.gz
TH0block_6hr_BR2_TR1_Run1.fastq.gz
TH0block_6hr_BR2_TR1_Run2.fastq.gz
TH1_0.5hr_BR1_TR1_Run1.fastq.gz
TH1_0.5hr_BR1_TR2_Run1.fastq.gz
TH1_0hr_BR1_TR1_Run1.fastq.gz
TH1_0hr_BR1_TR2_Run1.fastq.gz
TH1_2hr_BR1_TR1_Run1.fastq.gz
TH1_2hr_BR1_TR2_Run1.fastq.gz
TH1_6hr_BR1_TR1_Run1.fastq.gz
TH1_6hr_BR1_TR2_Run1.fastq.gz
TH17_0.5hr_BR1_TR1_Run1.fastq.gz
TH17_0.5hr_BR1_TR2_Run1.fastq.gz
TH17_0.5hr_BR1_TR3_Run1.fastq.gz
TH17_0.5hr_BR2_TR1_Run1.fastq.gz
TH17_0.5hr_BR2_TR2_Run1.fastq.gz
TH17_0.5hr_BR2_TR3_Run1.fastq.gz
TH17_0hr_BR1_TR1_Run1.fastq.gz
TH17_0hr_BR1_TR2_Run1.fastq.gz
TH17_0hr_BR1_TR3_Run1.fastq.gz
TH17_0hr_BR2_TR1_Run1.fastq.gz
TH17_0hr_BR2_TR2_Run1.fastq.gz
TH17_0hr_BR2_TR3_Run1.fastq.gz
TH17_2hr_BR1_TR1_Run1.fastq.gz
processed data file
Foxp3IL10neg_Ohr_BR1_TR1-All_Aligned_Reads.bw
Foxp3IL10neg_Ohr_BR2_TR1-All_Aligned_Reads.bw
Foxp3IL10neg_Ohr_BR3_TR1-All_Aligned_Reads.bw
Foxp3IL10pos_Ohr_BR1_TR1-All_Aligned_Reads.bw
Foxp3IL10pos_Ohr_BR2_TR1-All_Aligned_Reads.bw
Foxp3IL10pos_Ohr_BR3_TR1-All_Aligned_Reads.bw
Naive_0.5hr_BR1_TR1-All_Aligned_Reads.bw
Naive_0.5hr_BR2_TR1-All_Aligned_Reads.bw
Naive_0.5hr_BR2_TR2-All_Aligned_Reads.bw
Naive_0.5hr_BR2_TR3-All_Aligned_Reads.bw
Naive_Ohr_BR1_TR1-All_Aligned_Reads.bw
Naive_Ohr_BR1_TR2-All_Aligned_Reads.bw
Naive_Ohr_BR1_TR3-All_Aligned_Reads.bw
Naive_Ohr_BR2_TR1-All_Aligned_Reads.bw
Naive_Ohr_BR2_TR2-All_Aligned_Reads.bw
Naive_Ohr_BR2_TR3-All_Aligned_Reads.bw
Naive_2hr_BR1_TR1-All_Aligned_Reads.bw
Naive_2hr_BR1_TR2-All_Aligned_Reads.bw
Naive_2hr_BR1_TR3-All_Aligned_Reads.bw
Naive_2hr_BR2_TR1-All_Aligned_Reads.bw
Naive_2hr_BR2_TR2-All_Aligned_Reads.bw
Naive_2hr_BR2_TR3-All_Aligned_Reads.bw

Naive_6hr_BR1_TR1-All_Aligned_Reads.bw
Naive_6hr_BR1_TR2-All_Aligned_Reads.bw
Naive_6hr_BR2_TR1-All_Aligned_Reads.bw
Naive_6hr_BR2_TR2-All_Aligned_Reads.bw
Naive_6hr_BR2_TR3-All_Aligned_Reads.bw
TH0_0.5hr_BR1_TR1-All_Aligned_Reads.bw
TH0_0.5hr_BR1_TR2-All_Aligned_Reads.bw
TH0_0.5hr_BR1_TR3-All_Aligned_Reads.bw
TH0_0.5hr_BR2_TR1-All_Aligned_Reads.bw
TH0_0.5hr_BR2_TR2-All_Aligned_Reads.bw
TH0_0.5hr_BR2_TR3-All_Aligned_Reads.bw
TH0_0hr_BR1_TR1-All_Aligned_Reads.bw
TH0_0hr_BR1_TR2-All_Aligned_Reads.bw
TH0_0hr_BR1_TR3-All_Aligned_Reads.bw
TH0_0hr_BR2_TR1-All_Aligned_Reads.bw
TH0_0hr_BR2_TR2-All_Aligned_Reads.bw
TH0_0hr_BR2_TR3-All_Aligned_Reads.bw
TH0_2hr_BR1_TR1-All_Aligned_Reads.bw
TH0_2hr_BR1_TR2-All_Aligned_Reads.bw
TH0_2hr_BR1_TR3-All_Aligned_Reads.bw
TH0_2hr_BR2_TR1-All_Aligned_Reads.bw
TH0_2hr_BR2_TR2-All_Aligned_Reads.bw
TH0_2hr_BR2_TR3-All_Aligned_Reads.bw
TH0_6hr_BR1_TR1-All_Aligned_Reads.bw
TH0_6hr_BR1_TR2-All_Aligned_Reads.bw
TH0_6hr_BR1_TR3-All_Aligned_Reads.bw
TH0_6hr_BR2_TR1-All_Aligned_Reads.bw
TH0_6hr_BR2_TR2-All_Aligned_Reads.bw
TH0_6hr_BR2_TR3-All_Aligned_Reads.bw
TH0block_0.5hr_BR1_TR1-All_Aligned_Reads.bw
TH0block_0.5hr_BR1_TR1-All_Aligned_Reads.bw
TH0block_0.5hr_BR2_TR1-All_Aligned_Reads.bw
TH0block_0.5hr_BR2_TR1-All_Aligned_Reads.bw
TH0block_0hr_BR1_TR1-All_Aligned_Reads.bw
TH0block_0hr_BR1_TR1-All_Aligned_Reads.bw
TH0block_0hr_BR2_TR1-All_Aligned_Reads.bw
TH0block_0hr_BR2_TR1-All_Aligned_Reads.bw
TH1_0.5hr_BR1_TR1-All_Aligned_Reads.bw
TH1_0.5hr_BR1_TR2-All_Aligned_Reads.bw
TH1_0hr_BR1_TR1-All_Aligned_Reads.bw
TH1_0hr_BR1_TR2-All_Aligned_Reads.bw
TH1_2hr_BR1_TR1-All_Aligned_Reads.bw
TH1_2hr_BR1_TR2-All_Aligned_Reads.bw
TH1_6hr_BR1_TR1-All_Aligned_Reads.bw
TH1_6hr_BR1_TR2-All_Aligned_Reads.bw
TH17_0.5hr_BR1_TR1-All_Aligned_Reads.bw
TH17_0.5hr_BR1_TR2-All_Aligned_Reads.bw
TH17_0.5hr_BR2_TR1-All_Aligned_Reads.bw
TH17_0.5hr_BR2_TR2-All_Aligned_Reads.bw
TH17_0.5hr_BR2_TR3-All_Aligned_Reads.bw
TH17_0hr_BR1_TR1-All_Aligned_Reads.bw
TH17_0hr_BR1_TR2-All_Aligned_Reads.bw
TH17_0hr_BR1_TR3-All_Aligned_Reads.bw
TH17_0hr_BR2_TR1-All_Aligned_Reads.bw
TH17_0hr_BR2_TR2-All_Aligned_Reads.bw
TH17_0hr_BR2_TR3-All_Aligned_Reads.bw
4. Provide a link to an anonymized genome browser session (e.g. UCSC), if available.

Methodological details

5. Describe the experimental replicates.

The Assay for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq) was carried out on CD4+ T cells from each of the three disease models (Malaria, HDM allergy, and EAE). There were three biological replicates for each of the two genotypes (c-Maffl/fl and c-Maf fl/fl CD4Cre).

6. Describe the sequencing depth for each experiment.

All ATAC-seq samples were sequenced using Illumina HiSeqs2500, paired-end. Data is described as follows:
Sample ID – sequencing depth, length of reads. Quantity of reads remaining after
data processing, described in supplementary information.

Malaria Maf fl/fl:
GAN719A3: 355024714 (x2) reads, length 51 nt. Quality control and processing resulted in 173310313 reads.
GAN719A21: 312476181 (x2) reads, length 51 nt. Quality control and processing resulted in 147589106 reads.
GAN719A22: 322625689 (x2) reads, length 51 nt. Quality control and processing resulted in 134514415 reads.

Malaria Maf fl/fl CD4Cre:
GAN719A4: 350641802 (x2) reads, length 51 nt. Quality control and processing resulted in 134514415 reads.
GAN719A11: 355324979 (x2) reads, length 51 nt. Quality control and processing resulted in 147486992 reads.
GAN719A12: 356720441 (x2) reads, length 51 nt. Quality control and processing resulted in 147402576 reads.

HDM allergy Maf fl/fl:
GAN719A5: 342362988 (x2) reads, length 51 nt. Quality control and processing resulted in 147402576 reads.
GAN719A15: 345626232 (x2) reads, length 101 nt. Quality control and processing resulted in 123984864 reads.
GAN719A17: 309429135 (x2) reads, length 51 nt. Quality control and processing resulted in 134272611 reads.

HDM allergy Maf fl/fl CD4 Cre:
GAN719A6: 356793270 (x2) reads, length 51 nt. Quality control and processing resulted in 153200843 reads.
GAN719A18: 327015288 (x2) reads, length 101 nt. Quality control and processing resulted in 123984864 reads.
GAN719A27: 180711873 (x2) reads, length 101 nt. Quality control and processing resulted in 97866988 reads.

EAE Maf fl/fl:
GAN719A20: 171209809 (x2) reads, length 51 nt. Quality control and processing resulted in 40686167 reads.
GAN719A24: 178313808 (x2) reads, length 101 nt. Quality control and processing resulted in 45610741 reads.
GAN719A26: 186452585 (x2) reads, length 101 nt. Quality control and processing resulted in 51441647 reads.

EAE Maf fl/fl CD4 Cre:
GAN719A19: 167390937 (x2) reads, length 51 nt. Quality control and processing resulted in 39080438 reads.
GAN719A23: 171694244 (x2) reads, length 101 nt. Quality control and processing resulted in 39847852 reads.
GAN719A25: 189463614 (x2) reads. Length 101 nt. Quality control and processing resulted in 50105695 reads.

7. Describe the antibodies used for the ChIP-seq experiments.

8. Describe the peak calling parameters.

9. Describe the methods used to ensure data quality.

Illumina Nextera kit Cat #FC-121-1030 was used to generate libraries, amplified for 11 cycles with Nextera PCR Primers.

MACS2 2.1.1 software was used to call peaks with the following parameters:
--keep-dup all: do not remove duplicated alignment (already removed using Picard software)
--nomodel --shift -100 --extsize 200: selected according to software documentation to look for enrichment of insertion sites (Tn5 transposase)
selected all peaks with q-value < 0.01 (default parameter)
A consensus peak set was retrieved per disease model (called with a q-value < 0.01). Due to the minimal changes in accessibility, peaks called irrespective of their genotype were considered. The quantities of peaks analysed go as follows: malaria: 87533, HDM: 54745, EAE: 42286 peaks. See also supplementary information.

FastQC_0.11.5: for overall quality assessment
Skewer 0.2.2: sequencing quality control
IGV_2.3.97: genome browser visual inspection of ATAC-seq peaks in BED format
SAMtools 1.3.1 for alignment QC (discarded alignments with a mapQ < 30)
MACS2 2.1.1 software was used to call peaks with the following parameters:
--keep-dup all: do not remove duplicated alignment (already removed using Picard
software)
--nomodel --shift -100 --extsize 200: selected according to software documentation
to look for enrichment of insertion sites (Tn5 transposase)
selected all peaks with q-value < 0.01 (default parameter)
A consensus peak set was retrieved per disease model (called with a q-value <
0.01). Due to the minimal changes in accessibility, peaks called irrespective of their
genotype were considered. The quantities of peaks analysed go as follows: malaria:
87533, HDM: 54745, EAE: 42286 peaks. See also supplementary information.

10. Describe the software used to collect and analyze
the ChIP-seq data.

FastQC_0.11.5: for overall quality assessment
BWA-MEM: map pair-end reads to mm10
BEDTools 2.26.0: convert alignments from bam to bed format
Awk: command line tool. Used to remove alignments done to mitochondrial DNA,
shift reads in the forward strand by +4bp or reverse strand by -5 bp, and to
remove fragments with a size >99bp.
MACS2 2.1.1: peak-calling
Diffbind 2.0.2: peak read quantification to test for differential changes in chromatin
accessibility.
BaGFoot: test for differential TF activity based on changes in Tn5 insertions on
motif matching sites.
DeepTools 2.4.2: bamCoverage command to retrieve RPKM normalised
IGV_2.3.97: genome browser visual inspection of ATAC-seq peaks in BED format
R statistical software for data integration and visualization.
See also supplementary information.
ChIP-seq Reporting Summary

Form fields will expand as needed. Please do not leave fields blank.

Data deposition

1. For all ChIP-seq data:
   - Confirm that both raw and final processed data have been deposited in a public database such as GEO.
   - Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

2. Provide all relevant data deposition access links.
   *The entry may remain private before publication.*

3. Provide a list of all files available in the database submission.

4. Provide a link to an anonymized genome browser session (e.g. UCSC), if available.

Methodological details

5. Describe the experimental replicates.
   - In our study, we used a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918).
   - The two available replicates for c-Maf ChIP-seq (SRA IDs: SRR571559, SRR571560) and one input sample (SRR571773) were analysed.

6. Describe the sequencing depth for each experiment.
   - All ChIP-seq sequencing reads were single-ended.
   - Sample ID – sequencing depth, length of reads. Quantity of reads remaining after data processing, described in supplementary information.

7. Describe the antibodies used for the ChIP-seq experiments.
   - MACS2 2.1.1 software was used to call peaks with the following parameters:
     default parameters, suitable for ChIP-seq analysis. Selected all peaks with q-value < 0.01 (default parameter). For each replicate, peaks were called individually and used the same ChIP input sample for both. See also supplementary information.

8. Describe the peak calling parameters.
   - Not Applicable. Used publicly available GEO dataset: GSE40918

9. Describe the methods used to ensure data quality.
   - FastQC_0.11.5: for overall quality assessment
   - IGV_2.3.97: genome browser visual inspection of ChIP-seq peaks in BED format
   - MACS2 2.1.1 software was used to call peaks with the following parameters:
     default parameters, suitable for ChIP-seq analysis. Selected all peaks with q-value < 0.01 (default parameter). For each replicate, peaks were called individually and used the same ChIP input sample for both. See also supplementary information. A consensus peak set was generated from the union of both replicates (peaks with a q-value < 0.01). For overlapping peaks between replicates, the one with the highest confidence score was kept. This resulted in 45,727 c-Maf ChIP-seq peaks. See also supplementary information.

10. Describe the software used to collect and analyze the data.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.
    - Not applicable, a previously published c-Maf ChIP-seq dataset, Ciofani et al. Cell (2012) (GEO ID: GSE40918) was used.

---

Corresponding author(s): Dr. Anne O’Garra
10. Describe the software used to collect and analyze the ChIP-seq data.

- **Bowtie 1.1.2**: map single-end reads (parameters y -m 2 --best --strata -S)
- **BEDTools 2.26.0**: convert alignments from bam to bed format
- **MACS2 2.1.1**: peak-calling
- **IGV_2.3.97**: genome browser visual inspection of ChIP-seq peaks in BED format
- **R statistical software**: for data integration and visualization.

See also supplementary information.